Document:

EX-10.2

 Exhibit 10.2 

EXECUTIVE EMPLOYMENT 

AGREEMENT BY AND BETWEEN 

HORIZON PHARMA USA, INC. AND 

DR. JEFFERY KENT 
 This
Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware
corporation, each having a principal place of business at 150 S. Saunders Road, Lake Forest, IL 60045, (hereinafter referred to together as the “Company”) and Dr. Jeffery Kent (hereinafter referred as to the
“Executive”).The terms of this Agreement shall be effective commencing May 1, 2019 (the “Effective Date”). 

RECITALS 
 WHEREAS,
the Company desires assurance of the continued association and services of the Executive in order to continue to retain the Executive’s experience, skills, abilities, background and knowledge, and is willing to continue to engage the
Executive’s services on the terms and conditions set forth in this Agreement; and 
 WHEREAS, Executive desires to be in the
continued employ of the Company, and is willing to accept such continued employment on the terms and conditions set forth in this Agreement, which as of the Effective Date shall replace and supersede in its entirety the terms of the Prior Agreement.

 AGREEMENT 
 1. Employment.

 1.1 Term. The Executive originally commenced employment with the Company on May 14, 2012. The Company hereby agrees
to continue to employ the Executive, and the Executive hereby accepts continued employment by the Company, upon the terms and conditions set forth in this Agreement. Executive’s employment shall be governed under the terms set forth in this
Agreement beginning on the Effective Date and shall continue until it is terminated pursuant to Section 4 herein (hereinafter referred to as the “Term”). 

1.2 Title. From and after the Effective Date the Executive will have the title of senior vice president, head of medical affairs
and outcomes research (such position held by Executive during such period is hereinafter referred to as “SVP”) and Executive shall continue to serve in such other capacity or capacities commensurate with his position as SVP
as the President and CEO of the Company may from time to time prescribe. 
 1.3 Duties. The Executive shall do and perform all
services, acts or things necessary or advisable to manage and conduct the business of the Company and shall have the authority and responsibilities which are generally associated with the position of SVP including being responsible for the
Company’s business units. The Executive shall report to the President and CEO. 

 1.4 Policies and Practices. The employment relationship between the parties
shall be governed by this Agreement and the policies and practices established by the Company and the Board of Directors (hereinafter referred to as the “Board”). In the event that the terms of this Agreement differ from
or are in conflict with the Company’s policies or practices or the Company’s Employee Handbook, this Agreement shall control. 

1.5 Location. The Executive shall perform the services the Executive is required to perform pursuant to this Agreement in at the
Company’s U.S. Headquarters in Lake Forest Illinois. The Company may from time to time require the Executive to travel temporarily to other locations outside of Lake Forest, Illinois area in connection with the Company’s business. 

2. Loyalty of Executive. 
 2.1
Loyalty. During the Executive’s employment by the Company, the Executive shall devote the Executive’s business energies, interest, abilities and productive time to the proper and efficient performance of Executive’s duties
under this Agreement. Subject to the prior written consent of the President and CEO, the Executive is permitted to serve on the board of directors of one other company, so long as the other company does not compete with the Company. 

2.2 Exclusive Employment. Except with the prior written consent of the Chief Executive Officer, Executive shall not, during the
term of this Agreement, undertake or engage in any other employment, occupation or business enterprise, other than ones in which Executive is a passive investor. The Company specifically agrees that the Executive may engage in any civic and not-for-profit board membership or activities (including, but not limited to Executive role on the board of the Arthritis Foundation) so long as such activities do not
materially interfere with the performance of his duties hereunder or present a conflict of interest with the Company. 
 2.3 Agreement not
to Participate in Company’s Competitors. During the Term of this Agreement, the Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by Executive to be adverse or
antagonistic to the Company, its business or prospects, financial or otherwise or in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its affiliates. Notwithstanding the
foregoing, Executive may invest and/or maintain investments in any public or private entity up to an amount of 2% of an entity’s fully diluted shares and on a passive basis. 

 3. Compensation to Executive. 

3.1 Base Salary. The Company shall pay the Executive a base salary at the initial annualized rate of Four Hundred Twenty Six
Thousand Thirty Seven Dollars ($426,037.00) per year, subject to standard deductions and withholdings, or such higher rate as may be determined from time to time by the Board or the compensation committee thereof (hereinafter referred to as the
“Base Salary”). Such Base Salary shall be paid in accordance with the Company’s standard payroll practice. Payments of salary installments shall be made no less frequently than once per month. Executive’s Base
Salary will be reviewed annually and Executive shall be eligible to receive a salary increase (but not decrease) annually in an amount to be determined by the Board or the compensation committee thereof in its sole and exclusive discretion. Once
increased, the new salary shall become the Base Salary for purposes of this Agreement and shall not be reduced without the Executive’s written consent. Any material reduction in the Base Salary of the Executive, without his written consent, may
be deemed Good Reason as set forth in and subject to Section 4.5.2 of this Agreement. 
 3.2 Discretionary Bonus. Provided
the Executive meets the conditions stated in this Section 3.2, the Executive shall be eligible for an annual discretionary bonus (hereinafter referred to as the “Bonus”) with a target amount of fifty percent (50%) of the
Executive’s Base Salary, subject to standard deductions and withholdings, based on the Board’s determination, in good faith, and based upon the Executive’s individual achievement and company performance objectives as set by the Board
or the compensation committee thereof, of whether the Executive has met such performance milestones as are established for the Executive by the Board or the compensation committee thereof, in good faith, in consultation with the Executive
(hereinafter referred to as the “Performance Milestones”). The Performance Milestones will be based on certain factors including, but not limited to, the Executive’s performance and the Company’s financial
performance. The Executive’s Bonus target will be reviewed annually and may be adjusted by the Board or the compensation committee thereof in its discretion, provided however, that the Bonus target may only be materially reduced upon
Executive’s written consent. The Executive must be employed on the date the Bonus is awarded to be eligible for the Bonus, subject to the termination provisions thereof. The Bonus shall be paid during the calendar year following the performance
calendar year. 
 3.3 Prior Equity Grants. All Company equity awards previously granted to Executive shall continue in effect
from and following the Effective Date in accordance with their existing terms. Executive may be eligible to receive additional grants of Company equity awards in the sole discretion and subject to the approval of the Board. 

3.4 Legal Review. Upon the Executive’s submission of appropriate proof and verification of reasonable and customary legal
fees incurred by the Executive in obtaining legal advice associated with the review, preparation, approval, and execution of this Agreement, the Company shall pay for up to $10,000.00 of such legal fees subject to receipt of appropriate proof and
verification of such legal fees no later than sixty (60) days of receipt of an invoice for legal services from the Executive and/or his attorneys. To be eligible for reimbursement, the invoice must be submitted no later than ninety
(90) days after the legal fees are incurred. 

 3.5 Changes to Compensation. The Executive’s compensation may be changed
from time to time by mutual agreement of the Executive and the Company. In the event that the Executive’s Base Salary is materially decreased without his written consent, said decrease will be Good Reason for the Executive to terminate the
Agreement as set forth in and subject to Section 4.5.2 of this Agreement. Without limitation, Executive shall be entitled to participate in the Company sponsored 401k and Deferred Compensation plans and other compensation/benefit plans in which
Executive now participates. 
 3.6 Taxes. All amounts paid under this Agreement to the Executive by the Company will be paid
less applicable tax withholdings and any other withholdings required by law or authorized by the Executive. 
 3.7 Benefits.
The Executive shall, in accordance with Company policy and the terms of the applicable plan documents, be eligible to participate in benefits under any executive benefit plan or arrangement which may be in effect from time to time and made available
to the Company’s executives or key management employees, provided, however, that the Executive shall be entitled to at least four (4) weeks of paid vacation annually. 

3.8 Expense Reimbursement. The Company shall reimburse the Executive for all reasonable and necessary out-of-pocket expenses incurred by Executive in the performance of his executive duties and responsibilities hereunder, including without limitation expenses incurred for all
of Executive’s travel and accommodations, subject to the Company’s normal policies and procedures, including without limitation, for expense verification and documentation (it being understood by the parties hereto that the
Executive’s duties hereunder will differ in scope and intensity from Company’s non-executive employees). 

4. Termination. 
 4.1 Termination
by the Company. The Executive’s employment with the Company may be terminated only under the following conditions: 
 4.1.1
Termination for Death or Disability. The Executive’s employment with the Company shall terminate effective upon the date of the Executive’s death or “Complete Disability” (as defined in Section 4.5.1), provided,
however, that this Section 4.1.1 shall in no way limit the Company’s obligations to provide such reasonable accommodations to the Executive and/or his heirs as may be required by law. 

4.1.2 Termination by the Company For Cause. The Company may terminate the Executive’s employment under this Agreement for
“Cause” (as defined in Section 4.5.3) by delivery of written notice to the Executive specifying the Cause or Causes relied upon for such termination, provided that such notice is delivered within two (2) months following the
occurrence or discovery of any event or events constituting “Cause”. Any notice of termination given pursuant to this Section 4.1.2 shall effect termination as of the date of the notice or such date as specified in the notice. The
Executive shall have the right to appear before the CEO before any termination for Cause becomes effective and binding upon the Executive. 

 4.1.3 Termination by the Company Without Cause. The Company may terminate the
Executive’s employment under this Agreement at any time and for any reason or no reason subject to the requirements set out in Section 4.4 of this Agreement. Such termination shall be effective on the date the Executive is so informed or
as otherwise specified by the Company, pursuant to notice requirements set forth in Section 6 of this Agreement. 
 4.2
Termination By The Executive. The Executive may terminate his employment with the Company at any time and for any reason or no reason, including, but not limited, to the following conditions: 

4.2.1 Good Reason. The Executive may terminate his employment under this Agreement for “Good Reason” (as defined below
in Section 4.5.2) by delivery of written notice to the Company specifying the Good Reason(s) relied upon by the Executive for such termination in accordance with the requirements of such section. 

4.2.2 Without Good Reason. The Executive may terminate the Executive’s employment hereunder for other than Good Reason upon
thirty (30) days written notice to the Company. 
 4.3 Termination by Mutual Agreement of the Parties. The
Executive’s employment pursuant to this Agreement may be terminated at any time upon a mutual agreement in writing of the parties. Any such termination of employment shall have the consequences specified in such mutual agreement. 

4.4 Compensation to Executive Upon Termination. In connection with any termination of the Executive’s employment for any
reason, the Executive or the Executive’s estate, as applicable, shall be entitled to any amounts payable to the Executive or the Executive’s beneficiaries subject to and accordance with the terms of the Company’s employee welfare
benefit plans or policies (excluding any severance pay), as well as any other compensation and benefits specified in this Agreement. 

4.4.1 Death or Complete Disability. If the Executive’s employment shall be terminated by his death or Complete Disability as
provided in Section 4.1.1, the Company shall pay to Executive, and/or Executive’s heirs, all earned but unpaid Base Salary earned through the date of termination, any earned but unpaid discretionary Bonuses for any prior period at such
time as bonuses would have been paid if the Executive remained employed, all accrued but unpaid business expenses, and all accrued but unused vacation time earned through the date of termination at the rate in effect at the time of termination
(hereinafter collectively referred to as the “Accrued Amounts”), less standard deductions and withholdings. The Executive shall also be eligible to receive a pro-rated Bonus for the
year in which the date of termination occurs, as determined by the Board or the Compensation Committee of the Board based on Executive’s then-current target Bonus and based on actual performance and the period of the year he was employed
(hereinafter referred to as the “Pro-rata Bonus”), less standard deductions and withholdings, to be paid as a lump sum within thirty (30) days after the date of termination. 

 4.4.2 With Cause or Without Good Reason. If the Executive’s employment
shall be terminated by the Company for Cause, or if the Executive terminates employment hereunder without Good Reason, the Company shall pay the Executive’s Base Salary earned through the date of termination, his accrued but unpaid business
expenses and his accrued and unused vacation benefits earned through the date of termination at the rate in effect at the time of termination, less standard deductions and withholdings. 

4.4.3 Without Cause or For Good Reason. 

(i) Not in Connection With a Change in Control. If the Company terminates the Executive’s employment without Cause or the
Executive terminates his employment for Good Reason, and Section 4.4.3(ii) below does not apply, the Company shall pay the Accrued Amounts subject to standard deductions and withholdings, to be paid as a lump sum no later than thirty
(30) days after the date of termination. In addition, subject to the limitations stated in this Agreement and upon the Executive’s furnishing to the Company an executed waiver and release of claims (the form of which is attached hereto as
Exhibit A) (the “Release”) within the applicable time period set forth therein, but in no event later than forty-five days following termination of employment and permitting such Release to become effective in accordance
with its terms (the “Release Effective Date”), and subject to Executive entering into no later than the Release Effective Date a non-competition agreement to be effective during the
Severance Period (as defined below), substantially similar to Section 2.3, and continuing to abide by its terms during the Severance Period, the Executive shall be entitled to: 

(a) the equivalent of the Executive’s Base Salary in effect at the time of termination will continue to be paid for a period of
twelve (12) months following the date of termination (hereinafter referred to as the “Non Change in Control Severance Period”), less standard deductions and withholdings, to be paid during the Non Change in Control
Severance Period according to the Company’s regular payroll practices, subject to any delay in payment required by Section 4.6 in connection with the Release Effective Date; and 

(b) in the event the Executive timely elects continued coverage under COBRA, the Company will continue to pay the same portion of
Executive’s COBRA health insurance premium as the percentage of health insurance premiums that it paid during the Executive’s employment, including any amounts that Company paid for benefits to the qualifying family members of the
Executive, following the date of termination up until the earlier of either (i) the last day of the Non Change in Control Severance Period or, (ii) the date on which the Executive begins
full-time employment with another company or business entity which offers comparable health insurance coverage to the Executive (such period, the “Non Change in Control COBRA Payment
Period”). Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law
(including, without limitation, Section 2716 of the Public Health 

 
Service Act), the Company shall in lieu thereof pay Executive a taxable cash amount, which payment shall be made regardless of whether the Executive or his qualifying family members elect COBRA
continuation coverage (the “Health Care Benefit Payment”). The Health Care Benefit Payment shall be paid in monthly or bi-weekly installments on the same schedule that the COBRA
premiums would otherwise have been paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have paid for COBRA insurance premiums (which amount shall be calculated based on the premium
for the first month of coverage), and shall be paid until the expiration of the Non Change in Control COBRA Payment Period. 
 (ii)
In Connection With a Change in Control. If the Company (or its successor) terminates the Executive’s employment without Cause or the Executive terminates his employment for Good Reason within the period commencing three (3) months
immediately prior to a Change in Control of the Company and ending eighteen (18) months immediately following a Change in Control of the Company (as defined in Section 4.5.4 of this Agreement), the Executive shall receive the Accrued
Amounts subject to standard deductions and withholdings, to be paid as a lump sum no later than thirty (30) days after the date of termination. In addition, subject to the limitations stated in this Agreement and upon the Executive’s
furnishing to the Company (or its successor) an executed Release within the applicable time period set forth therein, but in no event later than forty-five days following termination of employment and permitting such Release to become effective in
accordance with its terms, and subject to Executive entering into no later than the Release Effective Date a non-competition agreement to be effective during the Severance Period, substantially similar to
Section 2.3, and continuing to abide by its terms during the Severance Period, then in lieu of (and not additional to) the benefits provided pursuant to Section 4.4.3(i) above, the Executive shall be entitled to: 

(a) the equivalent of the Executive’s Base Salary in effect at the time of termination will continue to be paid for a period of
eighteen (18) months following the date of termination (hereinafter referred to as the “Change in Control Severance Period”), less standard deductions and withholdings, to be paid during the Change in Control Severance
Period according to the Company’s regular payroll practices, subject to any delay in payment required by Section 4.6 in connection with the Release Effective Date; 

(b) one and half (1.5) times Executive’s target Bonus in effect at the time of termination, or if none, one and half (1.5) times
the last target Bonus in effect for Executive, less standard deductions and withholdings, to be paid in a lump sum within ten (10) days following the later of (i) the Release Effective Date, or (ii) the effective date of the Change in
Control; and 

 (c) in the event the Executive timely elects continued coverage under COBRA, the
Company will continue to pay the same portion of Executive’s COBRA health insurance premium as the percentage of health insurance premiums that it paid during the Executive’s employment, including any amounts that Company paid for benefits
to the qualifying family members of the Executive, following the date of termination until the expiration of the Change in Control Severance Period. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company
cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay
Executive the Health Care Benefit Payment, which payment shall be made regardless of whether the Executive or his qualifying family members elect COBRA continuation coverage. The Health Care Benefit Payment shall be paid in monthly or bi-weekly installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer. The Health Care Benefit Payment shall be equal to the amount that the Company otherwise would have
paid for COBRA insurance premiums (which amount shall be calculated based on the premium for the first month of coverage), and shall be paid until the expiration of the Change in Control Severance Period. 

(iii) No Duplication of Benefits. For the avoidance of doubt, in no event will Executive be entitled to benefits under
Section 4.4.3(i) and Section 4.4.3(ii). If Executive commences to receive benefits under Section 4.4.3(i) due to a qualifying termination prior to a Change in Control and thereafter becomes entitled to benefits under
Section 4.4.3(ii), any benefits previously provided to Executive under Section 4.4.3(i) shall offset the benefits to be provided to Executive under Section 4.4.3(ii) and shall be deemed to have been provided to Executive pursuant to
Section 4.4.3(ii). 
 4.4.4 Equity Award Acceleration. 

(i) Not in Connection With a Change in Control. In the event that the Executive’s employment is terminated without Cause or
for Good Reason and Section 4.4.4 (ii) below does not apply, the vesting of any equity awards granted to Executive that vest solely subject to Executive’s continued services to the Company (the “Time-Based Vesting Equity
Awards”) shall be deemed vested and immediately exercisable (if applicable) by the Executive with respect to such number of shares as determined in accordance with their applicable vesting schedules as if Executive had provided an
additional twelve (12) months of services as of the date of termination. Treatment of any performance based vesting equity awards granted to Executive will in all cases be governed solely by the terms of the equity award plan and/or agreement
under which they were granted and will not be eligible to accelerate vesting pursuant to the foregoing provision. 
 (ii) In
Connection With a Change in Control. In the event that the Executive’s employment is terminated without Cause or for Good Reason within the three (3) months immediately preceding or during the eighteen (18) months immediately
following a Change in Control of the Company (as defined in Section 4.5.4 of this Agreement), the vesting of any Time-Based Vesting Equity Awards 

 
granted to Executive shall be fully accelerated such that on the effective date of such termination (or if later, the date of the Change in Control) one hundred percent (100%) of any
Time-Based Vesting Equity Awards granted to Executive prior to such termination shall be fully vested and immediately exercisable, if applicable, by the Executive. Treatment of any performance based vesting equity awards granted to Executive
will in all cases be governed solely by the terms of the equity award plan and/or agreement under which they were granted and will not be eligible to accelerate vesting pursuant to the foregoing provision 

(iii) Release and Waiver. Any equity vesting acceleration pursuant to this Section 4.4.4 shall be conditioned upon and
subject to the Executive’s delivery to the Company of a fully effective Release in accordance with the terms specified by Section 4.4.3 hereof and such vesting acceleration benefit shall be in addition to the benefits provided by
Section 4.4.3 hereof. 
 4.5 Definitions. For purposes of this Agreement, the following terms shall have the following
meanings: 
 4.5.1 Complete Disability. “Complete Disability” shall mean the inability of the Executive
to perform the Executive’s duties under this Agreement, whether with or without reasonable accommodation, because the Executive has become permanently disabled within the meaning of any policy of disability income insurance covering employees
of the Company then in force. In the event the Company has no policy of disability income insurance covering employees of the Company in force when the Executive becomes disabled, the term “Complete Disability” shall mean the
inability of the Executive to perform the Executive’s duties under this Agreement, whether with or without reasonable accommodation, by reason of any incapacity, physical or mental, which the Board, based upon medical advice or an opinion
provided by a licensed physician, determines to have incapacitated the Executive from satisfactorily performing all of the Executive’s usual services for the Company, with or without reasonable accommodation, for a period of at least one
hundred eighty (180) days during any twelve (12) month period that need not be consecutive. 
 4.5.2 Good Reason.
“Good Reason” for the Executive to terminate the Executive’s employment hereunder shall mean the occurrence of any of the following events without the Executive’s consent: 

(i) a material reduction in the Executive’s duties, authority, or responsibilities relative to the duties, authority, or
responsibilities in effect immediately prior to such reduction, including by way of example, having the same title, duties, authority and responsibilities at a subsidiary level following a Change in Control; 

(ii) the relocation of the Executive’s primary work location to a point more than fifty (50) miles from the Executive’s
current work location set forth in Section 1.5 that requires a material increase in Executive’s one-way driving distance; 

 (iii) a material reduction by the Company of the Executive’s Base Salary or
annual target Bonus opportunity, without the written consent of the Executive, as initially set forth herein or as the same may be increased from time to time pursuant to this Agreement; and 

(iv) a material breach by the Company of Section 1.2 of this Agreement. 

Provided, however that, such termination by the Executive shall only be deemed for Good Reason pursuant to the foregoing definition if (i) the
Company is given written notice from the Executive within sixty (60) days following the first occurrence of the condition that he considers to constitute Good Reason describing the condition and the Company fails to satisfactorily remedy such
condition within thirty (30) days following such written notice, and (ii) the Executive terminates employment within thirty (30) days following the end of the period within which the Company was entitled to remedy the condition
constituting Good Reason but failed to do so. 
 4.5.3 Cause. “Cause” for the Company to terminate
Executive’s employment hereunder shall mean the occurrence of any of the following events, as determined reasonably and in good faith by the Board or a committee designated by the Board: 

(i) the Executive’s gross negligence or willful failure to substantially perform his duties and responsibilities to the Company or
willful and deliberate violation of a Company policy; 
 (ii) the Executive’s conviction of a felony or the Executive’s
commission of any act of fraud, embezzlement or dishonesty against the Company or involving moral turpitude that is likely to inflict or has inflicted material injury on the business of the Company, to be determined by the sole discretion of the
Company; 
 (iii) the Executive’s unauthorized use or disclosure of any proprietary information or trade secrets of the Company
or any other party that the Executive owes an obligation of nondisclosure as a result of the Executive’s relationship with the Company; and 

(iv) the Executive’s willful and deliberate breach of the obligations under this Agreement that causes material injury to the
business of the Company. 
 4.5.4 Change in Control. For purposes of this Agreement, “Change in
Control” means: (i) a sale of all or substantially all of the assets of the Company; (ii) a merger or consolidation in which the Company is not the surviving entity and in which the holders of the Company’s outstanding
voting stock immediately prior to such transaction own, immediately after such transaction, securities representing less than fifty percent (50%) of the voting power of the entity surviving such transaction or, where the surviving entity is a
wholly-owned subsidiary of another entity, the surviving entity’s 

 
parent; (iii) a reverse merger in which the Company is the surviving entity but the shares of Common Stock outstanding immediately preceding the merger are converted by virtue of the merger
into other property, whether in the form of securities of the surviving entity’s parent, cash or otherwise, and in which the holders of the Company’s outstanding voting stock immediately prior to such transaction own, immediately after
such transaction, securities representing less than fifty percent (50%) of the voting power of the Company or, where the Company is a wholly-owned subsidiary of another entity, the Company’s parent; or (iv) an acquisition by any person,
entity or group (excluding any employee benefit plan, or related trust, sponsored or maintained by the Company or subsidiary of the Company or other entity controlled by the Company) of the beneficial ownership of securities of the Company
representing at least seventy-five percent (75%) of the combined voting power entitled to vote in the election of Directors; provided, however, that nothing in this paragraph shall apply to a sale of assets, merger or other transaction effected
exclusively for the purpose of changing the domicile of the Company. 
 4.6 Application of Internal Revenue Code
Section 409A. Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement (the “Severance Benefits”) that constitute “deferred
compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations and other guidance thereunder and any state law of similar effect (collectively
“Section 409A”) shall not commence in connection with Executive’s termination of employment unless and until Executive has also incurred a “separation from service” (as such
term is defined in Treasury Regulation Section 1.409A-1(h) (“Separation From Service”), unless the Company reasonably determines that such amounts may be provided to Executive
without causing Executive to incur the additional 20% tax under Section 409A. 
 It is intended that each installment of the Severance
Benefits payments provided for in this Agreement is a separate “payment” for purposes of Treasury Regulation Section 1.409A-2(b)(2)(i). For the avoidance of doubt, it is intended that payments
of the Severance Benefits set forth in this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulation Sections
1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if the Company (or, if applicable, the successor entity thereto)
determines that the Severance Benefits constitute “deferred compensation” under Section 409A and Executive is, on the termination of service, a “specified employee” of the Company or any successor entity thereto, as such
term is defined in Section 409A(a)(2)(B)(i) of the Code, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Severance Benefit payments shall be
delayed until the earlier to occur of: (i) the date that is six months and one day after Executive’s Separation From Service, or (ii) the date of Executive’s death (such applicable date, the “Specified Employee Initial
Payment Date”), the Company (or the successor entity thereto, as applicable) shall (A) pay to Executive a lump sum amount equal to the sum of the Severance Benefit payments that Executive would otherwise have received through the
Specified Employee Initial Payment Date if the commencement of the payment of the Severance Benefits had not been so delayed pursuant to this Section and (B) commence paying the balance of the Severance Benefits in accordance with the
applicable payment schedules set forth in this Agreement. 

 Notwithstanding anything to the contrary set forth herein, Executive shall receive the
Severance Benefits described above, if and only if Executive duly executes and returns to the Company within the applicable time period set forth therein, but in no event more than forty-five days following Separation From Service, the
Company’s standard form of release of claims in favor of the Company (attached to this Agreement as Exhibit A) (the “Release”) and permits the release of claims contained therein to become effective in accordance
with its terms (such latest permitted date, the “Release Deadline”). If the severance benefits are not covered by one or more exemptions from the application of Section 409A and the Release could become effective in the
calendar year following the calendar year in which Executive separates from service, the Release will not be deemed effective any earlier than the Release Deadline. Notwithstanding any other payment schedule set forth in this Agreement, none of the
Severance Benefits will be paid or otherwise delivered prior to the effective date (or deemed effective date) of the Release. Except to the extent that payments may be delayed until the Specified Employee Initial Payment Date pursuant to the
preceding paragraph, on the first regular payroll pay day following the effective date of the Release, the Company will pay Executive the Severance Benefits Executive would otherwise have received under the Agreement on or prior to such date but for
the delay in payment related to the effectiveness of the Release, with the balance of the Severance Benefits being paid as originally scheduled. 

The severance benefits are intended to qualify for an exemption from application of Section 409A or comply with its requirements to the
extent necessary to avoid adverse personal tax consequences under Section 409A, and any ambiguities herein shall be interpreted accordingly. 

4.7 Application of Internal Revenue Code Section 280G. If any payment or benefit Executive would receive
pursuant to a Change in Control from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be
subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the
Payment that would result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and
local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater economic benefit
notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction shall
occur in the manner that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata. 

 In the event it is subsequently determined by the Internal Revenue Service that some portion
of the Reduced Amount as determined pursuant to clause (x) in the preceding paragraph is subject to the Excise Tax, Executive agrees to promptly return to the Company a sufficient amount of the Payment so that no portion of the Reduced Amount
is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount is determined pursuant to clause (y) in the preceding paragraph, Executive will have no obligation to return any portion of the Payment pursuant to the preceding
sentence. 
 Unless Executive and the Company agree on an alternative accounting firm, the accounting firm engaged by the Company for
general tax compliance purposes as of the day prior to the effective date of the Change in Control shall perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual,
entity or group effecting the Change in Control, the Company shall appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such
accounting firm required to be made hereunder. 
 The Company shall use commercially reasonable efforts to cause the accounting firm engaged
to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to Executive and the Company within fifteen (15) calendar days after the date on which Executive’s right to a Payment is
triggered (if requested at that time by Executive or the Company) or such other time as requested by Executive or the Company. 
 4.8
Indemnification Agreements. The Company and the Executive have previously entered into indemnification agreements, copies of which are attached hereto as Exhibit B-1 and Exhibit B-2. 
 4.9 Confidential Information and Invention Assignment Agreement. The Executive has
previously executed the Company’s Confidential Information and Invention Assignment Agreement the terms of which shall continue to govern the terms of Executive’s employment following the Effective Date, and a copy of which is attached as
Exhibit C. 
 4.10 No Mitigation or Offset. The Executive shall not be required to seek or accept other employment, or
otherwise to mitigate damages, as a condition to receipt of the Severance Benefits, and the Severance Benefits shall not be offset by any amounts received by the Executive from any other source, except to the extent that the Executive’s rights
to the benefits described in Sections 4.4.3(i)(b) or 4.4.3(ii)(c), as applicable, are terminated by reason of the Executive obtaining full-time employment with another company or business entity which offers comparable health insurance coverage.

  

	5.	 Assignment and Binding Effect. 

This Agreement shall be binding upon the Executive and the Company and inure to the benefit of the Executive and the Executive’s heirs,
executors, personal representatives, assigns, administrators and legal representatives. Because of the unique 

 
and personal nature of the Executive’s duties under this Agreement, neither this Agreement nor obligations under this Agreement shall be assignable by the Executive. This Agreement shall be
binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives, provided that the Agreement may only be assigned to an acquirer of all or substantially all of the Company’s assets. Any such successor
of the Company will be deemed substituted for the Company under the terms of this Agreement for all purposes. For this purpose, “successor” means any person, firm, corporation or other business entity which at any time, whether by
purchase, merger or otherwise, directly or indirectly acquires all or substantially all of the assets or business of the Company. 
  

	6.	 Notice. 

For the purposes of this Agreement, notices, demands, and all other forms of communication provided for in this Agreement shall be in writing
and shall be deemed to have been duly given when delivered or (unless otherwise specified) mailed by registered mail, return receipt requested, postage prepaid, or by confirmed facsimile, addressed as set forth below, or to such other address as any
party may have furnished to the other in writing in accordance herewith, except that notices of address shall be effective only upon receipt, as follows: 

If to the Company: 
 Horizon
Pharma, Inc. 
 150 S. Saunders Road, 

Lake Forest, IL 60045 

Attention: Timothy P. Walbert, Chairman, President & CEO 

Fax: 847-572-1372 

If to the Executive: 

Dr. Jeffery Kent 
 1573
Stratford Road 
 Deerfield, IL 60015 
 Any
such written notice shall be deemed given on the earlier of the date on which such notice is personally delivered or five (5) days after its deposit in the United States mail as specified above. Either party may change its address for notices
by giving written notice to the other party in the manner specified in this section. 
  

	7.	 Choice of Law. 

This Agreement shall be governed by the laws of the State of Illinois, without regard to any conflicts of law principals thereof that would
call for the application of the laws of any other jurisdiction. The parties consent to the exclusive jurisdiction and venue of the federal court in the Northern District of Illinois, and state courts located in the state of Illinois, county of Cook.
Nothing in this Section 7 limits the rights of the parties to seek appeal of a decision of an Illinois court outside of Illinois that has proper jurisdiction over the decision of a court sitting in Illinois. 

	8.	 Integration. 

This Agreement, including Exhibit A, Exhibit B-1, Exhibit B-2
and Exhibit C contains the complete, final and exclusive agreement of the parties relating to the terms and conditions of the Executive’s employment and the termination of Executive’s employment, and supersedes all prior and
contemporaneous oral and written employment agreements or arrangements between the parties, including but not limited to the Prior Agreement. 
  

	9.	 Amendment. 

This Agreement cannot be amended or modified except by a written agreement signed by the Executive and the Company. 

 

	10.	 Waiver. 

No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the written consent of the party
against whom the wavier is claimed, and any waiver or any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant, condition or breach. 

 

	11.	 Severability. 

The finding by a court of competent jurisdiction of the unenforceability, invalidity or illegality of any provision of this Agreement shall not
render any other provision of this Agreement unenforceable, invalid or illegal. Such court shall have the authority to modify or replace the invalid or unenforceable term or provision with a valid and enforceable term or provision, which most
accurately represents the parties’ intention with respect to the invalid, unenforceable, or illegal term or provision. 
  

	12.	 Interpretation; Construction. 

The headings set forth in this Agreement are for convenience of reference only and shall not be used in interpreting this Agreement. This
Agreement has been drafted and negotiated by legal counsel representing the Company and the Executive. The parties acknowledge that each party and its counsel has reviewed and revised, or had an opportunity to review and revise, this Agreement, and
any rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. 
  

	13.	 Execution by Facsimile Signatures and in Counterparts. 

The parties agree that facsimile signatures shall have the same force and effect as original signatures. This Agreement may be executed in one
or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 

	14.	 Survival. 

The provisions of this Agreement, and of all other agreements referenced herein, shall survive the termination of this Agreement, and of the
Executive’s employment by the Company for any reason, to the extent necessary to enable the parties to enforce their respective rights hereunder. 

[Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREFORE, the parties have signed this Agreement on the date first
written above. 
 COMPANY: 
 HORIZON PHARMA USA, INC.

  

	
	By:
	
	Title: Chairman, President & CEO
	
	Print Name: Timothy P. Walbert

  

	
	 /s/ Timothy P. Walbert

	Signature

 As authorized agent of the Company 
  

	
	                                  
	Date

 EXECUTIVE: 
  

	
	 /s/ Dr. Jeffery Kent

	Dr. Jeffery Kent, individually
	
	5/1/19                        
	Date

 EXHIBIT A 

RELEASE AND WAIVER OF CLAIMS 

In consideration of the payments and other benefits set forth in Section 4.4 of the Executive Employment Agreement dated May 1, 2019,
(the “Employment Agreement”), to which this form is attached, I, Dr. Jeffery Kent, hereby furnish Horizon Pharma, Inc. and Horizon Pharma USA, Inc. (together the “Company”), with the following
release and waiver (“Release and Waiver”). 
 In exchange for the consideration provided to me by the Employment
Agreement that I am not otherwise entitled to receive, I hereby generally and completely release the Company and its directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities,
insurers, Affiliates, and assigns from any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring relating to my employment or the termination
thereof prior to my signing this Release and Waiver. This general release includes, but is not limited to: (1) all claims arising out of or in any way related to my employment with the Company or the termination of that employment;
(2) all claims related to my compensation or benefits from the Company, including, but not limited to, salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other
ownership interests in the Company; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (4) all tort claims, including, but not limited to, claims for fraud,
defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local statutory claims, including, but not limited to, claims for discrimination, harassment, retaliation, attorneys’ fees,
or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), the
Illinois Human Rights Act, the Illinois Equal Pay Act, the Illinois Religious Freedom Restoration Act, and the Illinois Genetic Information Privacy Act. Notwithstanding the foregoing, this Release and Waiver, shall not release or waive my rights: to
indemnification under the articles and bylaws of the Company, any and all indemnification agreements, or applicable law; to payments under Sections of the Employment Agreement; under any provision of the Employment Agreement that survives the
termination of that agreement; under any applicable workers’ compensation statute; under any option, restricted share or other agreement concerning any equity interest in the Company; as a shareholder of the Company or any other right that is
not waivable under applicable law. 
 I acknowledge that, among other rights, I am waiving and releasing any rights I may have under ADEA,
that this Release and Waiver is knowing and voluntary, and that the consideration given for this Release and Waiver is in addition to anything of value to which I was already entitled as an executive of the Company. If I am 40 years of age or older
upon execution of this Release and Waiver, I further acknowledge that I have been advised, as required by the Older Workers Benefit Protection Act, that: (a) the release 

 
and waiver granted herein does not relate to claims under the ADEA which may arise after this Release and Waiver is executed; (b) I should consult with an attorney prior to executing this
Release and Waiver; and (c) I have twenty-one (21) days from the date of termination of my employment with the Company in which to consider this Release and Waiver (although I may choose voluntarily
to execute this Release and Waiver earlier); (d) I have seven (7) days following the execution of this Release and Waiver to revoke my consent to this Release and Waiver; and (e) this Release and Waiver shall not be effective until the
seven (7) day revocation period has expired unexercised. If I am less than 40 years of age upon execution of this Release and Waiver, I acknowledge that I have the right to consult with an attorney prior to executing this Release and Waiver
(although I may choose voluntarily not to do so); and (c) I have five (5) days from the date of termination of my employment with the Company in which to consider this Release and Waiver (although I may choose voluntarily to execute this
Release and Waiver earlier). 
 I acknowledge my continuing obligations under my Confidential Information and Inventions Assignment Agreement
dated May 14, 2012. Pursuant to the Confidential Information and Inventions Assignment Agreement I understand that among other things, I must not use or disclose any confidential or proprietary information of the Company and I must immediately
return all Company property and documents (including all embodiments of proprietary information) and all copies thereof in my possession or control. I understand and agree that my right to the payments and other benefits I am receiving in exchange
for my agreement to the terms of this Release and Waiver is contingent upon my continued compliance with my Confidential Information and Inventions Assignment Agreement. 

This Release and Waiver, including my Confidential Information and Inventions Agreement dated May 14, 2012, constitutes the complete,
final and exclusive embodiment of the entire agreement between the Company and me with regard to the subject matter hereof. I am not relying on any promise or representation by the Company that is not expressly stated herein. This Release and Waiver
may only be modified by a writing signed by both me and a duly authorized officer of the Company. 
  

			
	Date:
		
	By:	 	  

		 	Dr. Jeffery Kent

 EXHIBIT B-1 

INDEMNIFICATION AGREEMENT 

 EXHIBIT B-2 

INDEMNIFICATION AGREEMENT 

 EXHIBIT C 

CONFIDENTIAL INFORMATION AND INVENTION ASSIGNMENT
AGREEMENTEX-10.3

 Exhibit 10.3 
  

							
	  
     

	 	                    	 	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE HORIZON THERAPEUTICS PLC HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL
AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO HORIZON THERAPEUTICS PLC IF PUBLICLY DISCLOSED.
	 		 	

 CONFIDENTIAL 

EXECUTION COPY 

COMMERCIAL SUPPLY 

AGREEMENT 
 BETWEEN

 CMC BIOLOGICS A/S, dba AGC Biologics 

and 
 HORIZON PHARMA
IRELAND LIMITED 
  

DISCLAIMER 

THIS DOCUMENT IS FOR DISCUSSION PURPOSES ONLY. IT IS NOT INTENDED TO CONSTITUTE ANY OFFER OR CREATE ANY LEGAL RELATIONS. 

THE SUPPLY OF THIS DOCUMENT IN ELECTRONIC FORM IS STRICTLY ON THE UNDERSTANDING THAT NO AMENDMENTS WILL BE MADE TO IT WHICH
ARE NOT EXLICITLY DRAWN TO THE OTHER PARTY’S ATTENTION EITHER BY MARKING THE CHANGES IN THE TEXT ITSELF OR OTHERWISE. 

  

			
		  	
	COMMERCIAL SUPPLY AGREEMENT	  	

 1 

 

 
 CONFIDENTIAL 

EXECUTION COPY 
 CONTENTS 

 

							
	 CONTENTS
	  	 	2	 
			
	 1.
	 	DEFINITIONS AND INTERPRETATION	  	 	4	 
			
	 2.
	 	MANUFACTURING SUPPLY AND APPLICABLE STANDARDS	  	 	13	 
			
	 3.
	 	CUSTOMER MATERIALS	  	 	15	 
			
	 4.
	 	TIMELINE, SPECIFICATION AND PROJECT MANAGEMENT	  	 	16	 
			
	 5.
	 	FORECASTS, ORDERS, MANUFACTURING CAPACITY AND SUPPLY FAILURE	  	 	18	 
			
	 6.
	 	PACKAGING, DELIVERY, STORAGE AND EXAMINATION	  	 	24	 
			
	 7.
	 	BATCH PRICE, PAYMENT TERMS AND MILESTONE PAYMENTS	  	 	27	 
			
	 8.
	 	CUSTOMER AUDITS, REGULATORY INSPECTIONS & MATTERS	  	 	30	 
			
	 9.
	 	WARRANTIES	  	 	32	 
			
	 10.
	 	CONFIDENTIAL INFORMATION	  	 	34	 
			
	 11.
	 	INTELLECTUAL PROPERTY	  	 	37	 
			
	12.	 	 INDEMNITIES AND LIABILITY
	  	 	39	 
			
	 13.
	 	PRODUCT RECALL	  	 	42	 
			
	 14.
	 	TERM AND TERMINATION	  	 	43	 
			
	 15.
	 	TECHNOLOGY TRANSFER	  	 	45	 
			
	 16.
	 	FORCE MAJEURE	  	 	47	 
			
	 17.
	 	APPLICABLE LAW, JURISDICTION AND DISPUTE RESOLUTION	  	 	47	 
			
	 18.
	 	MISCELLANEOUS	  	 	48	 
		
	 APPENDIX ONE
	  	 	53	 
		
	 APPENDIX TWO
	  	 	54	 

  

			
		  	
	COMMERCIAL SUPPLY AGREEMENT	  	

 2 

 CONFIDENTIAL 

 

 THIS COMMERCIAL SUPPLY AGREEMENT is made and effective as of February 14, 2018 (the
“Effective Date”). 
 BETWEEN 
  

	(1)	 CMC BIOLOGICS A/S, dba AGC Biologics, duly formed under the laws of Denmark and having its principal
place of business at Vandtaarnsvej 83B DK-2860 Soeborg, Copenhagen, Denmark (hereinafter referred to as “AGC”); and, 

 

	(2)	 HORIZON PHARMA IRELAND LIMITED, duly incorporated under the laws of Ireland and having its principal
place of business at Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, Ireland (hereinafter referred to as “Customer”). 

AGC and Customer may each be referred to herein as a “Party” and collectively as the
“Parties.” 
 RECITALS 
  

	(A)	 Customer is engaged in the research, development, manufacture and sale of new biologic products, including the
product designated by Customer as teprotumumab (“Product”); 

  

	(B)	 In addition to development and scale-up activities, AGC also provides
commercial manufacturing activities for biological products to pharmaceutical and biotechnology companies; and 

  

	(C)	 Customer wishes to contract with AGC to provide the Services (as defined below) for the commercial supply of
Product; and 

  

	(D)	 AGC is willing to provide the Services to the Customer on the terms and conditions set out in this Agreement in
exchange for the Batch Price which the Customer agrees to pay. 

  

			
		  	
	COMMERCIAL SUPPLY AGREEMENT	  	

 3 

 CONFIDENTIAL 

 

 NOW THEREFORE, THE PARTIES AGREE as follows: 

 

	1.	 DEFINITIONS AND INTERPRETATION 

 

	 	1.1	 For the purposes of this Agreement, the terms defined in this clause shall have the respective meanings set
forth below: 

  

			
		
	“Affiliate”	  	any company, partnership or other entity which directly or indirectly through one or more intermediaries controls or is controlled by, or is under common control with a Party. Solely for the purpose of this definition,
“control” and its correlates means the direct or indirect beneficial ownership of more than 50% of the voting share capital in such company, partnership or entity or the legal power to control the general management and policies of
such company, partnership or entity;
		
	“AGC Confidential Information”	  	AGC’s SOPs and non-public information relating to AGC Intellectual Property Rights;
		
	“AGC Facility”	  	AGC’s manufacturing facility in Copenhagen, Denmark or another AGC facility agreed on in writing by the Parties;
		
	“AGC Materials”	  	[***];
		
	“AGC Intellectual Property Rights”	  	All AGC Know-How and all Intellectual Property owned or Controlled by AGC or its Affiliates during the Term, in each case that is used in the Services or is otherwise reasonably useful or
necessary for the further processing, use, handling or sale of the Product;
		
	“AGC Know-How”	  	all Information owned or Controlled by AGC or its Affiliates during the Term which is not of general public knowledge;
		
	“Agreement”	  	this Agreement including all Appendices attached hereto and any amendments to the foregoing made in accordance with this Agreement;
		
	“Appendix” or “Appendices”	  	one or more of the appendices to this Agreement;

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 4 

 CONFIDENTIAL 

 

			
		
	“Batch”	  	a specific quantity of BDS that is intended to be of uniform character and quality and is produced during a single fermentation run (as defined by the applicable batch records) using the Cell Line at a specified fermenter
scale;
		
	“Batch Price”	  	the price payable for each Batch (including the purification, analytical and further processing steps applicable thereto) as initially described in the Appendix Two and as may be amended by written agreement between the Parties or
by operation of Clause 7.2;
		
	“Binding Order”	  	has the meaning set forth in Clause 5.8;
		
	“Bulk Drug Substance” or “BDS”	  	means the Product in bulk, as expressed by the Cell Line and harvested and purified in bulk from a fermentation run pursuant to the applicable Process;
		
	 “Business Day”
  

“Calendar Day”
  

“Calendar Quarter”
	  	 any day which is not a Saturday, a Sunday or a U.S. public holiday;

 
 any day;
  

a 3-month period beginning on January 1, April 1, July 1, or October 1 of each year;

		
	“Campaign”	  	a series of Batches manufactured consecutively in accordance with the Process;
		
	“Cell Line”	  	the mammalian cell line designated [***] which is owned by Customer and provided to AGC or derived from a master cell bank of the same strain as that provided by Customer to AGC and any progeny clone of the foregoing cell
line(s);
		
	“Certificate of Analysis” or “CoA”	  	a certificate of analysis in the form attached as Exhibit A confirming that Product to which the certificate relates meets the Specification and such other criteria as identified on the certificate;
		
	“Certificate of Compliance” or “CoC”	  	a certificate of compliance in the form attached as Exhibit B confirming that the Product to which the certificate relates was manufactured and supplied in compliance with cGMP and such other criteria as identified on the
certificate;    

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 5 

 CONFIDENTIAL 

 

			
		
	“cGMP”	  	Current Good Manufacturing Practices as promulgated under each of the following as in effect on the Effective Date and as amended or revised after the Effective Date: (a) the U.S. Food, Drug & Cosmetics Act (21 U.S.C.
§ 301 et seq.) and related U.S. regulations, including 21 Code of Federal Regulations (Chapters 210 and 211) and other FDA regulations, policies, or guidelines in effect at a particular time for the manufacture, testing and
quality control of investigational drugs; (b) EudraLex Volume 4; (c) the ICH guide Q7 “ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients;” and (d) any other laws, regulations and statutes set forth by a
Regulatory Authority applicable to the manufacture and supply of Product and other Services provided by AGC under this Agreement.
		
	“Change of Control”	  	 in relation to a body corporate, the occurrence of an event or circumstance where a Person who is not presently able to do any of the
following things becomes able to do one of the following things (whether directly or indirectly or through one or more intervening Persons):
  

(a) control the composition of more than one half of the body’s board of directors;

 
 (b) be in a position to cast, or control the casting of, more than one half of the
maximum number of votes that might be cast at a general meeting of the members of the body; or
  

(c) hold or have a beneficial interest in more than one half of the issued share capital of the body;

		
	“Commercial Quality Agreement”	  	the agreement between the Parties defining the quality responsibilities, including cGMP standards, regarding the performance of the Services, as further described in Clause 2.3;
		
	“[***]”	  	[***] of an experienced contract manufacturing organization engaged in the cGMP manufacture of biological products that are similar to the Product;
		
	“Confidential Information”	  	 means all Information owned or controlled by the Disclosing Party or its Affiliates that is disclosed to or made available to Recipient
Party relating to this Agreement and includes:
  

(I)     Information disclosed in writing, orally or by any other means;

		
		  	 (II)    Information disclosed before, after or on the date of this
Agreement;

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 6 

 CONFIDENTIAL 

 

			
		
		  	 (iii)    Information relating to the Disclosing Party’s operations,
products, processes, plans, intentions, market opportunities and business affairs, and any new and novel combinations thereof and any marketing and business plans, any financial (including pricing information) and personnel information relating to a
Party or its present or future products, sales, suppliers, customers, employees, investors or business; and
  

(iv)   the terms of this Agreement, which shall be deemed to be the Confidential Information of both
Parties.

		
		  	the use of which is governed according to the provisions of Clause 10;
		
	 “Conforming Product”
	  	BDS produced under cGMP that meets the Specifications;
		
	“Controlled”	  	 with respect to any material, Information or Intellectual Property of a Party, the possession or the ability by such Party to grant access, a
license, or a sublicense to such material, Information or Intellectual Property as provided for herein without violating an agreement with a Third Party;

		
	“Customer Intellectual Property Rights”	  	 All Customer Know-How and all Intellectual Property owned or Controlled by Customer or its Affiliates during the Term, in each case covering
any aspect of the Services, Cell Line, BDS or materials, techniques or processes used in the Services;

		
	“Customer Know-How”	  	 all Information owned or Controlled by Customer or its Affiliates during the Term which is not of general public knowledge;

		
	“Customer Materials”	  	(a) Customer-Provided Materials, and (b) [***];
		
	“Customer-Provided Materials”	  	the Cell Line, BI media and any other materials described in Appendix 2 that will be supplied to AGC by or on behalf of Customer, subject to Clause 3.4;
		
	“Defect” and “Defective”	  	have the meaning set forth in Clause 6.12;

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 7 

 CONFIDENTIAL 

 

			
		
	“Defect Notice”	  	has the meaning set forth in Clause 6.12;
		
	“Deliverables”	  	the data, results and materials generated from the performance of the Services including Batch records, CoA, CoC, electronic files of IPC (in-process control) and IPM (in-process monitoring) data, Drug History Records and Product. All Deliverables will be deemed to be Customer’s Confidential Information, excluding AGC Confidential Information;
		
	“Delivery” or “Delivered”	  	has the meaning set forth in Clause 6.3;
		
	“Delivery Date”	  	the month determined in accordance with Clause 5.6 for Delivery for the Product manufactured under a Purchase Order. Where a Timeline has been amended in accordance with Clause 4.2 or 4.3, the corresponding
Delivery Date shall be commensurately amended;
		
	“Drug History Record”	  	all lot disposition documentation relevant to a cGMP Batch to be provided to Customer with the Product from that cGMP Batch, including but not limited to manufacturing Batch records, Certificates of Compliance and Certificates of
Analysis;
		
	“Effective Date”	  	as set forth in the first paragraph of this Agreement;
		
	“EMA”	  	European Medicines Agency;
		
	“Exceptional Batches”	  	has the meaning in Clause 5.7;
		
	“FDA”	  	means the United States Food and Drug Administration, or its successor agency;
		
	“Firm Order”	  	has the meaning set out in Clause 5.3.1;
		
	“Forecast”	  	has the meaning set out in Clause 5.1;
		
	“Fundamental Change”	  	means a Change of Control, merger, acquisition or change of management of AGC;
		
	“Group”	  	in respect of the relevant Party, its Affiliates and holding companies and the Affiliates of those holding companies;

  

			
		  	
	COMMERCIAL SUPPLY AGREEMENT	  	

 8 

 CONFIDENTIAL 

 

			
		
	“Information”	  	techniques, data, discoveries, inventions, practices, methods, information, knowledge, know-how, test data (including pharmacological, toxicological and clinical test data), analytical and
quality control data, regulatory submissions and approvals, production information, expertise, methodologies, drawings, specifications, designs and trade secrets;
		
	“Initial Commitment Term”	  	The term commencing on the Effective Date and ending on the seventh (7th) anniversary thereof;
		
	“Intellectual Property”	  	all intellectual property rights, including, without limitation, patents, supplementary protection certificates, petty patents, utility models, trademarks, database rights, rights in designs, copyrights (whether or not any of
these are registered or capable of being registered) and including all applications and the right to apply for registered protection of the foregoing and all rights in Information, and all rights and forms of protection of a similar nature or having
equivalent or similar effect to any of these which may subsist anywhere in the world, in each case for their full term and together with any renewals or extensions;
		
	“Joint Steering Committee”	  	has the meaning set forth in Clause 4.7;
		
	“Minimum Volumes”	  	the minimum number of Batches that must be ordered per Calendar Year by Customer as stipulated in Clause 5.3.5;
		
	“Non-Fault Delays”	  	has the meaning set forth in Clause 4.1;
		
	“Person(s)”	  	any individual, partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed
herein;
		
	“Process”	  	the method for manufacture, harvesting and purification of the Product as defined in Customer approved manufacture batch records;
		
	“Product”	  	Customer’s biologic product which is a recombinant human anti-human insulin-like growth factor-l receptor monoclonal antibody, known as teprotumumab;
		
	“Project Manager”	  	has the meaning set forth in Clause 4.7;

  

			
		  	
	COMMERCIAL SUPPLY AGREEMENT	  	

 9 

 CONFIDENTIAL 

 

			
		
	“Project Team”	  	has the meaning set forth in Clause 4.8;
		
	“Raw Materials”	  	media, resins, catalysts, solvents, filters, membranes, disposable analytical test kits, disposable bags, and other items consumed for the manufacture of Products in accordance with this Agreement;
		
	“Recall”	  	any action to withdraw from supply or distribution or to recover title to or possession of quantities of Product sold or shipped to third parties (including, without limitation, the voluntary withdrawal of Product from the market
or correction) or the detention or destruction of any Product by any Regulatory Authorities;
		
	“Regulatory Authority”	  	any regulatory authority involved in regulating any aspect of the conduct, development, manufacture, market approval, sale, distribution, packaging or use of the Services or the Deliverables, including, without limitation, the
FDA and the EMA. “Regulatory Authority” also includes any non-governmental group licensed by an entity described in the preceding sentence to perform inspections, audits and/or reviews.
		
	“Regulatory Obligations”	  	those laws and regulatory requirements in [***] and any other jurisdiction agreed in writing by the Parties in accordance with Section 2.1.3, in each case applicable to the manufacture of cGMP Product for human
use;
		
	“Second Source”	  	any Third Party that is able to supply or procure the supply of Product or a product that is similar or equivalent to the Product;
		
	“Semi-Binding Order”	  	has the meaning set forth in Clause 5.3.3;
		
	“Services”	  	the manufacturing services to be conducted by AGC as described in this Agreement and the Commercial Quality Agreement;
		
	“Shipping Guidelines”	  	the storage and transport guidelines for the Product that are determined by mutual written agreement of the Parties;
		
	“Slot”	  	the period of time AGC’s cGMP manufacturing suite is reserved in preparation for and the manufacture of a Batch;

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 10 

 CONFIDENTIAL 

 

			
		
	“Specification”	  	the specification for the Product as defined in Appendix One or as may otherwise be agreed between the Parties in writing or modified in accordance with Clause 4.5. The Specification includes (i) specifications
for BDS and Raw Materials, (ii) manufacturing, testing and packaging instructions and specifications for Product in accordance with the Process, (iii) storage and shipping requirements, and (iv) any other technical information
necessary to manufacture a Batch;
		
	“Standard Operating Procedures” or “SOPs”	  	the standard operating procedures of AGC which define AGC’s methods of performing activities applicable to the Services;
		
	“Storage Cost”	  	has the meaning set forth in Clause 7.7;
		
	“Supply Failure”	  	 AGC’s failure, during any consecutive [***] month period, to Deliver at least the percentage set forth below (the “Designated
Percentage”) of the quantities of Conforming Product specified in Purchase Orders that have been submitted by Customer in accordance with its firm Forecast in accordance with the Delivery Date. Notwithstanding the foregoing, [***].

 
 The Designated Percentage shall be: (a) where the Firm Order is [***], and
(b) where the Firm Order is [***].

		
	“Term”	  	has the meaning set forth in Clause 14.1;
		
	“Testing Laboratories”	  	any Third Party approved in writing by Customer and instructed by AGC to carry out tests on the Cell Line, Customer Materials, BDS or Product pursuant to the performance or conformance of the Services with a
Specification;
		
	“Timeline”	  	collectively and individually, the timeline for AGC’s manufacture and Delivery of Product in accordance with the Forecast and each Delivery Date, and as may be amended in accordance with Clause 4.2 and 4.3;
and
		
	“Third Party”	  	means a Person other than the Parties and their respective Affiliates.

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 11 

 CONFIDENTIAL 

 

	 	1.2	 Additional Definitions. Each of the following definitions is set forth in the clause of this Agreement
indicated below: 

  

					
	 Definition:
	  	Clause:	 
	 Background Technology
	  	 	11.1	 
	 Binding Order
	  	 	5.8	 
	 AGC IPR
	  	 	11.4	 
	 Customer Agreement IPR
	  	 	11.3	 
	 Customer-Specific Infringement
	  	 	9.2.4	 
	 Joint IPR
	  	 	11.5	 
	 Lower Limit
	  	 	4.6	 
	 Indemnitee
	  	 	12.3	 
	 Indemnitor
	  	 	12.3.1	 
	 Producer Price Index
	  	 	7.2	 
	 Purchase Order
	  	 	5.6	 
	 Representatives
	  	 	4.8	 
	 Reserve Payment
	  	 	7.1	 
	 Target Yield
	  	 	4.6	 
	 Yield
	  	 	4.6	 

  

	 	1.3	 In this Agreement (except where the context otherwise requires): 

 

	 	1.3.1	 any reference to a recital, clause or appendix is to the relevant recital, clause or appendix of or to this
Agreement and any reference to a sub-clause or paragraph is to the relevant sub-clause or paragraph of the clause or appendix in which it appears; 

 

	 	1.3.2	 the table of contents and clause headings are included for convenience only and shall not affect the
interpretation of this Agreement; 

  

			
		  	
	COMMERCIAL SUPPLY AGREEMENT	  	

 12 

 CONFIDENTIAL 

 

	 	1.3.3	 use of the singular includes the plural and vice versa and use of any gender includes the other genders;

  

	 	1.3.4	 a reference to a “Party” is a reference to a party to this Agreement and a reference to a
“Party” includes a reference to that Party’s successors in title, permitted assignees and transferees (if any); 

  

	 	1.3.5	 “will”, “shall” and “must” are synonyms; 

 

	 	1.3.6	 “or” is used in the conjunctive (i.e., as “and/or”); 

 

	 	1.3.7	 “days”, if not otherwise specified, means Calendar Days; 

 

	 	1.3.8	 a reference to “writing” does not include email; and 

 

	 	1.3.9	 any phrase introduced by the terms “including”, “include”, “in particular” or any
similar expression shall be construed as illustrative and shall not limit the sense of the words preceding those terms. 

  

	 	1.4	 The Appendices form an integral part of this Agreement and shall have effect as if set out in full in the body
of this Agreement and any reference to this Agreement includes the Appendices hereto. 

  

	 	1.5	 Where there is any inconsistency between the Appendices and the main body of this Agreement, the conflicting
terms of the main body of this Agreement shall, unless expressly specified to the contrary, prevail. 

  

	2.	 MANUFACTURING SUPPLY AND APPLICABLE STANDARDS 

 

	 	2.1	 During the Term: 

2.1.1 AGC shall use [***] to manufacture Product in the quantity of Batches that are the subject of a Firm Order pursuant to the forecast
mechanism set out in Clause 5 and in accordance with the terms and requirements set out in this Agreement. Customer shall purchase from AGC the Product in the quantity of Batches in accordance with the terms of this Agreement. 

2.1.2 Notwithstanding the foregoing, and without reference to [***], AGC will manufacture and supply the Product hereunder in accordance with
the Specification, cGMP and the Regulatory Obligations. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 13 

 CONFIDENTIAL 

 

	 	2.1.3	 If Customer wishes to extend the scope of the Regulatory Obligations to cover jurisdictions beyond [***], the
Parties will discuss in good faith an amendment to this Agreement to do so. If the Parties do not execute such an amendment on mutually agreeable terms within [***] days of Customer’s written request to do so, then Customer will have the right
to have its requirements of BDS and Product solely for such jurisdiction manufactured by a Third Party, or to do so itself or through an Affiliate, notwithstanding any other provision of this Agreement. 

 

	 	2.2	 Where applicable, AGC will comply with the obligatory requirements stipulated in the International Conference
on Harmonisation guidelines on quality. 

  

	 	2.3	 AGC and Customer’s Affiliate Horizon Pharma Tepro, Inc. (“Horizon Tepro”) have entered
into that certain quality agreement dated October 10, 2017. Promptly following the Effective Date, but in any event within [***] days following the Effective Date unless mutually extended by the Parties, AGC and Horizon Tepro shall execute an
amendment to such quality agreement in order to assign such quality agreement from Horizon Tepro to Customer and to address the manufacture of Product under this Agreement. Upon the execution of such amendment, such quality agreement shall be deemed
to be the Commercial Quality Agreement. AGC will comply with quality standards as agreed to in the Commercial Quality Agreement. Any material breach of the Commercial Quality Agreement related to a quality matter will be deemed to be a material
breach of this Agreement. 

  

	 	2.4	 AGC shall retain and store samples of all cGMP Product released by AGC’s quality department with a
Certificate of Analysis under this Agreement for such period as may be required by applicable Regulatory Obligations, which in the absence of a definitive time period shall be [***] years from the date of release or Delivery. If the Parties agree,
AGC shall retain such samples for a longer period at the Customer’s cost. AGC will notify Customer in writing before disposing of any such samples and Customer will have the right to have such samples delivered to Customer or its designee at
Customer’s expense. 

 Third Party Testing Laboratories 

 

	 	2.5	 AGC may subcontract 

  

	 	2.5.1	 to its Affiliates, any part of the Services (provided that the Affiliates may not further subcontract those
parts of the Services), with the prior written consent of Customer (such consent not to be unreasonably withheld, delayed or conditioned); 

  

	 	2.5.2	 to Testing Laboratories which the Customer has approved in writing, Services identified in the applicable
Appendix as Services which AGC may subcontract to such Testing Laboratory(ies); 

  

	 	2.5.3	 to any other Third Party, any part(s) of the Services with the prior written consent of Customer (such consent
not to be unreasonably withheld, delayed or conditioned). 

 AGC shall remain directly and fully responsible to Customer
for the activities of the Person to which it subcontracts any of the Services. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 14 

 CONFIDENTIAL 

 

 Totality of Services 

 

	 	2.6	 The Services described in this Agreement, subject to any written agreement or amendment to the contrary, are
the only services to be performed by AGC hereunder. Due to the nature of the Services, changes to the Services may be necessary. Customer acknowledges this potential necessity and recognizes that any changes to Services may change the price for such
Services. 

  

	 	2.7	 If additional Services or a change to the Services is necessary, then the Parties shall promptly meet in good
faith to negotiate with respect to any such changes as may be necessary. Any such changes do not become effective until set forth in an amendment to this Agreement or other written agreement signed by an authorized representative of each Party.

  

	3.	 CUSTOMER MATERIALS; AGC MATERIALS  

 

	 	3.1	 All Raw Materials purchased by AGC for the Services will be the property of the Customer and deemed Customer
Materials. Customer hereby grants to AGC a security interest in all Raw Materials to secure the payment of any and all amounts due to AGC therefor. 

  

	 	3.2	 AGC will test, use, handle, store, transport, package and dispose of all Customer Materials in accordance with
all applicable laws and regulations, the applicable Materials Safety Data Sheet, the Commercial Quality Agreement, master Batch record and other applicable documentation, its applicable standard operating procedures (including, without limitation
those relating to cleaning and sterilization) and industry standards applicable to the contract manufacture of biologics. AGC shall qualify, oversee and audit its suppliers of the Customer Materials and the AGC Materials in accordance with
applicable cGMP requirements. The Parties agree to jointly work together to perform risk management analyses of vendors of the Customer Materials and Raw Materials, which shall include an assessment of the risks of interruption of supply from each
such vendor over the [***] year period covered by the Binding Orders. If either Party determines that there is a reasonable likelihood that there may be an interruption in supply from any such vendor or with respect to any Customer Material or Raw
Material it shall notify the Customer in writing and the Parties shall discuss in good faith risk mitigation strategies, which may include the payment by Customer of a reasonable stocking fee for the materials at issue. 

 

	 	3.3	 As between the Parties, AGC shall be solely responsible for the procurement and performance of the AGC
Materials. 

  

	 	3.4	 If, following the Effective Date, the Parties through the change control procedures set forth in the Commercial
Quality Agreement agree to changes in the Customer Materials (whether initiated by Customer or required by a Regulatory Authority), and [***]. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 15 

 CONFIDENTIAL 

 

	4.	 TIMELINE, SPECIFICATION AND PROJECT MANAGEMENT  

Timeline 
  

	 	4.1	 AGC shall use its [***] to maintain the Timeline for each Batch. Notwithstanding that obligation, the
Parties acknowledge and agree that the Timeline for a Batch may be varied as agreed by AGC and Customer in writing in order to accommodate delays or changes caused by or contributed to by (i) actions or omissions of the Customer (or its
agents); and/or (ii) additional activities added to the Services; and/or (iii) force majeure events or other circumstances beyond AGC’s reasonable control (“Non-Fault Delays”).

  

	 	4.2	 In the event of any Non-Fault Delays described in Clause 4.1(i)
or (ii), AGC shall update the Timeline for the applicable Batches as agreed in writing with the Customer and shall endeavor in good faith to keep the revised Timeline as close as possible to the Timeline in its form as it existed immediately
prior to the Non-Fault Delays. 

  

	 	4.3	 Notwithstanding Clause 18.4, the Timeline (for one or more Batches, or prospectively for all future
Batches) may be amended by agreement between AGC and Customer provided that the revised Timeline is set out and agreed in writing by the Project Team. 

  

	 	4.4	 Where the Timeline has been amended in accordance with this Clause 4, it shall be automatically binding
upon the Parties. AGC shall keep Customer updated as to its conformance with the Timeline for Batches then in production on a reasonable frequency. Customer may at any time on a reasonable basis request an update on performance of the Services
against the current Timeline. 

 Specification & Quantities 

 

	 	4.5	 The Parties agree that the Specification may be modified and updated by the Parties if agreed to by the Project
Team in writing and signed by an authorized representative of each Party. Each Party shall consider any proposed modifications to the Specification, including those that may be requested by a Regulatory Authority, in good faith. For the avoidance of
doubt, where the Parties cannot agree to modify, amend or update the Specification, the previous Specification as agreed to by the Parties shall apply. 

  

	 	4.6	 For clarity the Parties acknowledge that all quantities of BDS derived from a Batch [***]. Notwithstanding the
foregoing, [***] 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 16 

 CONFIDENTIAL 

 

 [***]. 

Project Manager, Joint Steering Committee and Project Team 
  

	 	4.7	 Each Party shall, within [***] days of the Effective Date, appoint an individual as a project leader
(“Project Manager”) who shall be responsible for leading and coordinating the day to day operation of the Services. In addition, within [***] days of the Effective Date, each Party shall select two of their senior technical staff,
one of whom (for each Party) may be a Project Manager, to form the steering committee who shall have responsibility for providing leadership and strategic oversight of the Services governed by this Agreement (“Joint Steering
Committee”). 

  

	 	4.8	 Separate from the Joint Steering Committee, the Parties shall form the “Project Team” that
will be responsible for the day to day performance of the Services including planning, executing and discussing issues regarding the Forecasts, the Timeline, the Services and communicating between the Parties. Any disputes or issues that cannot be
readily resolved by the Project Team shall be referred to the Joint Steering Committee for resolution. Each Party shall notify the other in writing of its representatives to the Project Team (“Representatives”), as may be changed
from time to time. 

  

	 	4.9	 Each Party’s Project Manager shall, subject to the oversight of the Joint Steering Committee,
(i) manage the relationship between the Parties, (ii) oversee the performance of the Services and the activities of the Project Team, (iii) undertake actions delegated to them by the Joint Steering Committee and (iv) be the
principal point of contact for the Services. The Project Managers shall meet upon reasonable request either in person or by telephone or video conference and each Party shall bear its own costs for attending such meetings. 

 

	 	4.10	 The Joint Steering Committee shall be responsible for (i) making decisions regarding issues outside the
scope of the Project Team or Project Managers directly relating to the manufacture and supply of Product hereunder, (ii) reviewing the decisions of the Project Team and/or Project Managers, (iii) providing a forum for the Parties to
exchange information and coordinate their respective activities regarding the Services, (iv) providing a forum to discuss any technical difficulties or changes to Services or Batch Price triggered by a change to the Services or in accordance
with Clause 7.3 as well as attempting in good faith to resolve any disputes or disagreements within the scope of its authority before escalation to the dispute resolution provided for in Clause 17, and (v) ensure that intent of
this Agreement is maintained throughout the Term The Joint Steering Committee shall meet on a reasonably regular basis during the Term. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 17 

 CONFIDENTIAL 

 

	 	4.11	 At regular intervals the Representatives shall schedule Project Team meetings for the purpose of overcoming any
issues with Forecasts, delivery of Product or the performance of all other aspects of the Services and providing an initial forum for discussing and resolving any difficulties or hurdles encountered in the performance of the Services. Such meetings
shall be conducted by telephone conference or, if necessary, by face-to-face meetings at an agreed frequency unless particular difficulties arise which dictate the need
for more frequent meetings. Each Party shall be responsible for their own costs in attending and conducting the Project Team meetings. 

  

	 	4.12	 Should either Party become aware or conclude that it is reasonably likely that AGC will be unable to meet the
Timeline or Delivery Dates for one or more Batches of Product in accordance with Firm Orders resulting in a halting or delay in the manufacture of the Product, then it shall promptly notify the other Party. AGC shall as soon as reasonably
practicable notify Customer of the circumstances of such delay and explain what efforts AGC is taking to address such delay, and the Parties shall discuss in good faith through the Project Team what steps may be taken to mitigate such delay.

  

	 	4.13	 Any decision by the Project Team, the Project Managers or Joint Steering Committee which has the effect of
amending the Services in any way must, before it becomes binding, be recorded in writing and signed by both Parties in accordance with Clause 18.4. 

 

	 	4.14	 In any decision to be made by the Project Team, the Project Managers or the Joint Steering Committee, each
Party shall have one vote, irrespective of the number of its representatives participating. 

  

	 	4.15	 The Project Team, Project Managers and Joint Steering Committee shall have no authority to amend this
Agreement, determine compliance with any provision of this Agreement, or waive any right or obligation under this Agreement. 

  

	5.	 FORECASTS, ORDERS, MANUFACTURING CAPACITY AND FAILURE TO SUPPLY 

Forecasts 
  

	 	5.1	 Commencing on the Effective Date, and thereafter at the beginning of each subsequent Calendar Quarter, Customer
shall, subject to the provisions of this clause, deliver to AGC a rolling [***] month forecast of Customer’s requirements for Product for the following [***] months (“Forecast”), subject to Clause 2.1.3.

  

	 	5.2	 Each Forecast shall set out the number of Batches of Product required by Customer during each Calendar Quarter
covered by the Forecast together with the requested delivery dates for Product in each Calendar Quarter covered by the Forecast. In preparing a Forecast Customer shall: 

 

	 	5.2.1	 Attempt to aggregate the number of Batches required throughout the period covered by the Forecast into
contiguous Campaigns; and 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 18 

 CONFIDENTIAL 

 

	 	5.2.2	 shall use reasonable efforts to provide a Forecast that accurately reflects its good faith anticipated
requirements for the period covered by the Forecast, subject to Clause 2.1.3. 

  

	 	5.3	 In respect of each Forecast: 

 

	 	5.3.1	 the first [***] Calendar Quarter periods covered by the Forecast shall be a definitive and binding order
on Customer (a “Firm Order”); 

  

	 	5.3.2	 the [***] Calendar Quarter periods covered by the Forecast shall be [***]% binding on Customer;

  

	 	5.3.3	 the [***] Calendar Quarter periods covered by the Forecast shall be [***]% binding on Customer
(the order referred to in Clause 5.3.2 and this Clause 5.3.3, a “Semi Binding Order”); 

  

	 	5.3.4	 the [***] Calendar Quarter periods covered by the Forecast shall not be binding on Customer; and serves
only as information to AGC for capacity planning purposes. 

  

	 	5.3.5	 Until the [***], Customer shall order at a minimum [***] Batches per Calendar Year. Thereafter,
Customer shall order a minimum of [***] Batches per Calendar Year. Such batches may be ordered as a campaigns or as single Batches. This minimum may be increased or decreased (but never below [***] Batches following the [***]) from time to time by
written agreement of the Parties. Once a [***]L Batch has been [***], the Parties shall engage in good faith discussions and agree upon a reasonable new minimum. The Parties understand and agree that Customer is liable for the Minimum Volume of
Batches required to be ordered for each Calendar Year during the Term of this Agreement at the then-current Batch Price, subject to Clauses 5.8 and 6.16. Notwithstanding the foregoing, the Parties agree that the Minimum Volume for
[***] shall be satisfied by the [***] Batches that Customer ordered for Delivery during [***] under the Development and Manufacturing Services Agreement dated as of June 10, 2015 (the “MSA”). Such [***] Batches shall be paid for in
accordance with the MSA and the applicable Work Statement(s) (as defined therein), notwithstanding Appendix Two. 

 AGC
shall reserve a minimum of [***] Slots per Calendar Year for Customer, but Customer shall be entitled to reserve additional slots that AGC may have available or upon [***] months’ written notice. The Parties shall discuss in good faith
increasing such minimum reservation as needed. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 19 

 CONFIDENTIAL 

 

	 	5.4	 The Forecasts are intended to provide AGC with clarity as to the Customer’s requirements for Product.
Forecasts shall be provided by Customer on a rolling quarterly basis as provided above and each subsequent Forecast shall reflect the previous relevant Forecasts provided by Customer such that: 

 

	 	5.4.1	 the quantity of Product set out in the [***] Calendar Quarter of the immediately preceding Forecast
shall, in the next Forecast, become the [***] Calendar Quarters of the Firm Order without any variation (other than with AGC’s prior written consent); 

  

	 	5.4.2	 the quantity of Product set out in the [***] Calendar Quarter of the immediately preceding Forecast shall, in
the next Forecast, become the [***] Calendar Quarter in the next Forecast and a Firm Order but may be varied by Customer by a maximum of [***]% in whole Batches or [***] Batch, whichever is the greater; 

 

	 	5.4.3	 the quantity of Product set out in the [***] Calendar Quarter of the immediately preceding Forecast shall, in
the next Forecast, become the [***] Calendar Quarters and Semi Binding Orders and may be varied by a maximum of [***]% in whole Batches or [***] Batches whichever is the greater; and 

 

	 	5.4.4	 Customer shall provide a new projection for the [***] Calendar Quarters in accordance with the principles set
out in Clause 5.3. 

  

	 	5.5	 If Customer fails to submit a Forecast in accordance with the preceding provisions of this Clause 5,
then a Forecast shall automatically be deemed to be served under this clause by Customer where: 

  

	 	5.5.1	 the first [***] Calendar Quarters of such new Forecast shall be identical to the [***] Calendar Quarters of the
immediately preceding Forecast; and 

  

	 	5.5.2	 the [***] Calendar Quarter of the new Forecast shall be identical in terms of the quantity of Batches
identified in the [***] Calendar Quarter of the immediately preceding Forecast; and 

  

	 	5.5.3	 the preferred delivery dates for the [***] Calendar Quarter of the new deemed Forecast shall be the preferred
delivery dates set out for the [***] Calendar Quarter of the immediately preceding Forecast, with each extended by a [***] month period. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 20 

 CONFIDENTIAL 

 

 Orders 
  

	 	5.6	 Customer shall provide a written or electronic purchase orders (each, a “Purchase
Order”) for each Firm Order in conformance with the relevant Forecast within [***] days of the updated Forecast. Each Purchase Order shall include a requested [***], which may be changed by AGC +/- by [***] days.
AGC shall provide written confirmation of such [***] to Customer within [***] days of receipt of the Purchase Order, and such confirmed [***] +/- [***] days shall thereafter be the Delivery Date. Each Purchase Order shall be in a form reasonably
acceptable to AGC and Customer. No terms contained in any Purchase Order, order acknowledgment or similar document shall be construed to amend or modify the terms of this Agreement and in the event of any conflict, this Agreement shall prevail and
control, unless the Parties otherwise expressly agree in writing by making reference to both this Agreement and the alternative terms. 

  

	 	5.7	 Notwithstanding the limits on ordering under a Forecast, AGC may, in response to Customer’s written
request, elect to manufacture additional Batches of Product in a Calendar Quarter beyond the quantity allocated in a Firm Order for that same Calendar Quarter (“Exceptional Batches”). AGC’s obligation to manufacture Exceptional
Batches shall only arise upon AGC’s written acceptance whereby the Exceptional Batches accepted by AGC shall be deemed part of the Firm Order(s) for the relevant Calendar Quarter(s). AGC shall use [***] to accept Customer’s orders for
Exceptional Batches. 

  

	 	5.8	 All quantities of Batches that are the subject of a Firm Order or the binding portion of a Semi-Binding Order
(collectively, a “Binding Order”) shall be binding upon Customer and may not be delayed or cancelled by Customer, except pursuant to Clause 5.12. 

 

	 	5.8.1	 Should Customer [***], then Customer shall [***], provided that commencing as of [***]. AGC shall be entitled
to invoice in [***], and Customer shall pay such invoice in accordance with the provisions of Clause 7. 

  

	 	5.8.2	 Should Customer [***], then Customer shall [***], provided that commencing as of [***]. AGC shall be entitled
to invoice [***], and Customer shall pay such invoice in accordance with the provisions of Clause 7. 

  

	 	5.8.3	 Customer’s payments under this Section 5.8 shall be AGC’s sole remedy for any cancellation of
any portion of a Binding Order. 

  

	 	5.9	 AGC shall be obliged to manufacture the quantity of Batches identified in a Binding Order and shall use its
[***] to meet the Timeline for Delivery of those Batches in accordance with Clause 2.1. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 21 

 CONFIDENTIAL 

 

	 	5.10	 AGC shall use the Forecasts to plan for and, as appropriate, reserve Slots in its cGMP manufacturing suite for
those Batches to be manufactured under a Binding Order to meet the applicable Delivery Dates according to the then-current Timeline. Upon the reasonable request of AGC, the Parties shall cooperate to seek an agreement in good faith to vary or amend
any part of a Forecast (including the Firm Orders, Semi Binding Orders, Timeline and Delivery Date) to accommodate lead times. 

  

	 	5.11	 Where the Timeline for one or more Batches is amended and such amendment effects the scheduled Slot(s) for
those Batches which are the subject of a Binding Order, AGC shall update its manufacturing schedule and reserve a new Slot for each affected Batch which, subject to reserved slots under AGC’s existing manufacturing schedule for its whole
facility, shall be reserved as near in time to the existing vacated Slots as AGC’s then current schedule will permit. 

Supply Failure 
  

	 	5.12	 If a Supply Failure occurs, the following shall apply, without limiting Customer’s other rights under this
Agreement: 

  

	 	5.12.1	 provided that such Supply Failure is not due to AGC’s negligence, willful misconduct or breach of this
Agreement, AGC and Customer shall work collaboratively to discuss and find ways to promptly overcome the Supply Failure and re-establish supply of Product as soon as practicable; 

 

	 	5.12.2	 Customer shall have the right to cancel any unfilled Purchase Orders and to engage another manufacturer for its
BDS and Product requirements. Customer will be entitled to a technology transfer to a Second Source in accordance with Clause 15. 

  

	 	5.12.3	 Customer shall have the right to use its Second Source to manufacture all or part of its requirements, and will
not be subject to the limit set forth in Clause 5.14 while a Supply Failure is ongoing. The number of Batches manufactured by such Second Source shall commensurately reduce the Minimum Volume for the current and subsequent Calendar Years. A
Supply Failure shall be deemed to be ongoing until such time as AGC can demonstrate to Customer’s reasonable satisfaction that AGC will be able to manufacture and Deliver Conforming Product in accordance with the then-current Timeline.

  

	 	5.12.4	 If a Supply Failure results from AGC’s negligence, intentional misconduct or breach of this Agreement or
the Commercial Quality Agreement [***], then Customer shall not be liable for any portion of any Binding Order which AGC could not deliver, the Minimum Volume commitment shall not apply and AGC shall promptly reimburse Customer for any
advance amounts paid by Customer in connection with such Batches. If a Supply Failure results from Customer’s negligence, intentional misconduct or breach of this Agreement or the Commercial

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 22 

 CONFIDENTIAL 

 

	 	
Quality Agreement [***] (and is not attributable to any failure to comply with cGMP by AGC), then Customer shall be liable for any portion of any Binding Order which AGC could not deliver
due to such Supply Failure (provided that any cancelled Batches shall be subject to Clause 5.8) and the Minimum Volume commitment shall continue to apply. If a Supply Failure does not result from either Party’s negligence, intentional
misconduct or breach or this Agreement or the Commercial Quality Agreement, and [***], or either Party disputes in good faith the cause of the Supply Failure, then the Parties shall negotiate in good faith an equitable allocation of costs for the
Batches affected by such Supply Failure, including any Purchase Orders cancelled by Customer in accordance with Section 5.12.2. 

  

	 	5.12.5	 AGC shall use reasonable efforts to sell to another customer capacity not previously reserved by that other
customer at the time of the Supply Failure, filling any Slot that would have been used by Customer had the Supply Failure not occurred. If AGC fills such Slot, then AGC shall reduce Customer’s liability for such Slot by a sum equal to the fee
paid or owed by the other customer. 

  

	 	5.12.6	 If and when AGC is able to demonstrate to Customer’s reasonable satisfaction that it can resume supply
after a Supply Failure, Customer shall resume manufacturing with AGC and cease its own or third party manufacturing of Product to meet Minimum Volumes, subject to Customer’s rights under Clause 5.14. 

 

	 	5.13	 AGC will not be deemed to be in breach of the Agreement solely because of the occurrence of a Supply Failure,
provided that AGC is not in material breach of any other provision of the Agreement and is continuing to use [***] to remedy the Supply Failure. Notwithstanding the foregoing, if AGC is unable to remedy a Supply Failure within [***] months following
the commencement of such Supply Failure despite using [***], then either Party shall have the right to terminate this Agreement upon [***] days prior notice. 

Second Source 
  

	 	5.14	 Customer shall have the right, at any time during the Term, to establish a Second Source in order to ensure
consistency of Product supply, provided that in no event shall AGC supply less than [***]% of Customer’s requirements for BDS except as provided in Clauses 2.1.3 and 5.12. AGC shall provide a technology transfer to such Second
Source and Customer will be entitled to a technology transfer to a Second Source in accordance with Clause 15. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 23 

 CONFIDENTIAL 

 

	6.	 PACKAGING, DELIVERY, STORAGE AND EXAMINATION 

Packaging 
  

	 	6.1	 All Cell Lines, Product and perishable Deliverables to be Delivered shall be packaged by AGC in accordance with
its applicable packaging SOPs and Regulatory Obligations. AGC will accommodate reasonable Customer specific packaging requests. 

Delivery 
  

	 	6.2	 AGC shall provide Customer with advance notice of each anticipated date of Delivery and, in any event, shall
provide at least [***] Business Days advance notice of each date AGC is to Deliver Product to Customer or Customer’s shipping company. 

  

	 	6.3	 Except as set out in Clause 6.5 or in the Specifications, the Product that AGC manufactures pursuant to
this Agreement shall be [***]. The Product will be deemed to have been delivered upon the date Product is [***] (“Deliver”, “Delivery” or “Delivered”). Collection may be arranged at any time during
normal business hours on Business Days or such other time as may be agreed by the Parties. 

  

	 	6.4	 [***] shall not be responsible for or have an obligation to [***] pursuant to this Agreement.

  

	 	6.5	 AGC shall deliver data, results, Batch records, CoA, CoC, IPC
(in-process control) and IPM (in-process monitoring) data in form of electronic files (e.g. excel files), and Drug History Records to Customer or its designee by mail or
electronic mail. 

 Release For Further Processing 

 

	 	6.6	 Subject to Regulatory Obligations and cGMP, Customer may, by written notice, request that AGC Deliver Product
to Customer prior to AGC issuing a Certificate of Analysis for such Product (“Release For Further Processing”). Any Product that is the subject of Release For Further Processing shall, until the applicable Certificate of Analysis is
issued by AGC: 

  

	 	6.6.1	 not be administered to any human; 

 

	 	6.6.2	 be handled by Customer with reasonable care and attention and treated with caution as if it were an unknown
substance; 

  

	 	6.6.3	 be accepted at Customer’s sole risk and liability and AGC shall not be liable for any loss or damage
caused by Product which is the subject of Release For Further Processing other than for death or personal injury caused by AGC’s negligence, gross negligence or intentional misconduct. 

Title and Risk 
  

	 	6.7	 Title and risk in the Deliverables shall pass to Customer on Delivery. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 24 

 CONFIDENTIAL 

 

 Storage and Transport 

 

	 	6.8	 Where Customer elects to have a shipping company or other agent (“Shipping Company”) collect
and transport the Product upon Delivery, Customer shall, prior to the collection of the Product, inform AGC of its designated Shipping Company. Customer shall coordinate with such Shipping Company for the shipment of the Product and AGC shall not be
responsible for any shipping costs of the Shipping Company. 

  

	 	6.9	 If Customer or Customer’s Shipping Company is unable to collect a Product scheduled to be picked up at the
time of Delivery, AGC shall, upon the Customer’s request, store at its facility any such Product for a period of [***] Business Days after Delivery on behalf of Customer (the “Initial Storage Period”). Storage of Product at
AGC’s premises after the Initial Storage Period shall be at Customer’s sole risk and liability except that AGC shall be responsible for damage to such Product to the extent any damage is caused during such storage by an act of AGC’s
[***]. If Product has not been collected by Customer or Customer’s Shipping Company by the end of the Initial Storage Period, AGC shall notify Customer in writing of the outstanding collection. AGC shall be entitled, commencing [***] Business
Days after Customer’s receipt of such notice, to charge Customer $[***] per week per Batch for the continued storage of such Deliverable, unless the Parties have previously negotiated for longer term storage. 

 

	 	6.10	 Customer may, prior to Delivery, request that AGC arranges for storage of Product prior to the Product being
transported to a location specified by Customer (“Alternative Site”) subsequent to its Delivery. Where AGC agrees to such a request: 

  

	 	6.10.1	 Customer shall provide AGC with [***] the Alternative Site; 

 

	 	6.10.2	 storage organized by AGC shall be at AGC’s sole cost, risk and liability; and 

 

	 	6.10.3	 AGC shall, in the Customer’s name and at the Customer’s cost, insure the Product until such time as
they are transported to the Alternative Site. 

  

	 	6.11	 If Customer shall or intends to examine or test the Product and wishes to reserve its right to make a claim
against AGC under this Article 6 in respect of a Defect in such Product, Customer undertakes to ensure that such Product since collection from AGC’s Facility or transport to the Alternative Site has been stored and transported in
accordance with the applicable Shipping Guidelines. Failure by Customer to comply with such Shipping Guidelines in a manner that could reasonably cause or contribute the occurrence of such Defect before or after serving a Defect Notice (as defined
below) will invalidate Customer’s right to make any claim under this Agreement in respect of such Product. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 25 

 CONFIDENTIAL 

 

 Examination of Deliverables for Defects etc. 

 

	 	6.12	 Following their Delivery, Customer shall promptly examine and test the Deliverables for any defect or non-conformity, including in the case of Product or BDS non-conformity with the Specifications and cGMP standards which Deliverables are specified to meet (a
“Defect”, with such Product or BDS being “Defective”). Where any alleged Defect is identified, Customer shall notify AGC by written notice (“Defect Notice”) (a) within [***] Business Days of
Customer’s or its agent’s receipt of the Deliverables, other than for Latent Defects, and (b) within [***] Business Days of becoming aware of a Latent Defect. A “Latent Defect” means a Defect that cannot be reasonably
detected by the testing procedures used by Customer. AGC will have no liability for a Latent Defect unless [***]. 

  

	 	6.13	 A Defect Notice must identify (i) the Deliverable and, in the case of Product, the Batch from which the
Product was derived, (ii) the date(s) of Delivery and collection (or where the Deliverables are transported to the Alternative Site, the date received at the Alternative Site), (iii) reasonable detail, including test results, of the Defect,
(iv) where applicable, disclosure of the methodology of all analytical tests performed on the Deliverables and the results of those tests, (v) confirmation that the Deliverables have been stored and transported in accordance with the
applicable Shipping Guidelines and (vi) where the Customer asserts that the Defect is due to AGC, the reasons why the Customer makes that assertion. If a Defect in any Deliverable is not notified to AGC in accordance with the provisions and
time limits stipulated in Clauses 6.12, the Deliverable shall be deemed accepted and free of Defects and, Customer shall have no further remedy against AGC in respect of that Deliverable under this Clause 6. For clarity, nothing
in this Clause 6.13 shall affect AGC’s indemnification obligations under Clause 12. 

  

	 	6.14	 Upon receipt of the Defect Notice, AGC shall promptly investigate whether or not the Defect is due to
AGC’s negligence or failure to comply with its obligations hereunder and shall report to Customer within [***] Calendar Days of receipt of the Deliverables whether it accepts responsibility for the Defect in full, in part or not.

  

	 	6.15	 If there is a dispute regarding whether or not a Deliverable is Defective (“Disputed
Deliverable”), then (a) personnel from both Parties will directly communicate to determine the Parties’ respective methods of analysis are the same and are being executed in the same manner, and to attempt to determine whether any
non-compliance may have been caused during the shipment of the Deliverable from AGC’s Facility, and (b) carefully controlled and split samples as agreed should be sent from one site to another for
testing in an attempt to reach agreement (which may involve Customer sending a representative and a sample of the Disputed Deliverable to AGC, and the Parties conducting jointly agreed upon tests on the Customer sample of the Disputed Deliverable
and a sample of the Disputed Deliverable retained by AGC). The Parties will use good faith efforts for a period of [***] days after completing such tests to resolve whether the Disputed Deliverable is Defective due to AGC’s failure to
manufacture in accordance with this Agreement. In the event the Parties cannot resolve their dispute in the manner described, a mutually agreed-upon independent laboratory shall be engaged to test the Disputed Deliverable. The costs of such
independent laboratory 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 26 

 CONFIDENTIAL 

 

	 	
shall initially be borne by the Parties equally; provided, however, the Party that is determined by such laboratory to be incorrect in the dispute shall be responsible for all such reasonable out
of pocket costs in engaging such laboratory and shall reimburse the correct Party for its share of such reasonable costs incurred. The decision of such independent laboratory shall be in writing and shall be binding on both AGC and Customer. With
respect to all Product that Customer properly rejects, Customer shall destroy all remaining unused Product as soon as possible after AGC’s request. In no event may Customer use any of the rejected Product for any human clinical testing or
trials after it becomes aware of the basis for such rejection (and Customer shall indemnify AGC for all liabilities, costs and damages incurred by AGC resulting from Customer’s breach of this limitation on use in accordance with Clause
12). 

 Consequences of Defective Product 
  

	 	6.16	 If Customer can demonstrate or if the independent laboratory pursuant to Clause 6.15 determines that the
Defect is not the result of any wrongful action or inaction by Customer or a Customer-Provided Materials (or, if attributable to the Customer-Provided Materials, is the result of any failure to comply with cGMP by AGC) or any Third Party (other than
a contractor or agent of AGC performing Services), then AGC shall replace the Defective Deliverables. AGC shall use its [***] to commence the manufacture of such Defective Deliverables within [***] days after AGC accepts fault or is determined to be
at fault pursuant to Clause 6.15, [***]. In the event AGC cannot commence the manufacture of a replacement single Batch within such [***] days period or within [***] days after the end of a campaign if the Defective Batch was part of a
campaign, [***]. Any amounts paid by Customer hereunder for such Defective Deliverables shall be credited to future amounts due to AGC hereunder, and any residual amounts existing at the time of termination of this Agreement shall be subject to
Clause 14.4. 

  

	 	6.17	 The remedies and obligations under Clause 6.16 shall be Customer’s sole remedy for Defective
Deliverables, subject to Clause 12.2 (Indemnity of Customer). 

  

	7.	 BATCH PRICE, PAYMENT TERMS AND MILESTONE PAYMENTS 

Reserve Payment and Batch Price 
  

	 	7.1	 Customer shall make an initial payment of [***] Euros [***] and a further payment of [***] Euros [***]
(collectively, the “Reserve Payment”). Following approval of the BLA for the Product, AGC shall, at Customer’s election, reimburse the Reserve Payment or offset the Reserve Payment against future Batches. Additional payment for
Batches will be due as described in Appendix Two. The Batch Price in 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 27 

 CONFIDENTIAL 

 

 Appendix Two is stated in Euros and is exclusive of all taxes, duties, or other fees of
whatever nature imposed by or under the authority of any state, government or public authority (other than taxes on AGC’s income), or any external costs, Raw Materials or shipping and associated costs that AGC incurs to provide the Services,
which Customer agrees to pay in addition to the Batch Price. 
  

	 	7.2	 The Batch Price stated in Appendix Two may increase on an annual basis on the anniversary of the Effective
Date, commencing in [***], in accordance with the Producer Price Index that is applicable on the date of such anniversary of the Effective Date. The “Producer Price Index” means the Producer Price Index published by the
Bureau of Labor Statistics (or if such index is discontinued, the successor index or, if none, such other similar index mutually agreed upon by the Parties). 

  

	 	7.3	 If there are any material and unforeseen changes in cGMP or manufacturing regulations promulgated pursuant to
enabling legislation under a statute that: 

  

	 	7.3.1	 are specific to the Product and not of general requirement for biologics contract manufacturing services; or

  

	 	7.3.2	 which result in the financial returns under this Agreement being substantially affected to AGC’s detriment
other than by the acts or omissions of AGC, 

 then the Parties shall negotiate in good faith a way to continue the
Services to comply with such changes and/or address the financial detriment. 
 Invoicing & Payment Terms 

 

	 	7.4	 All invoices will be in Euros and Customer agrees to pay all sums due hereunder in Euros.

  

	 	7.5	 AGC will issue invoices in accordance with the provisions of Appendix Two. 

 

	 	7.6	 All invoices shall be paid by wire transfer to the following account: 

ACCOUNT DETAILS: 

[***] 
 SWIFT:

 [***] 

Bank accounts details: 

[***] 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 28 

 CONFIDENTIAL 

 

 [***] 

Unless expressly stated on an invoice to the contrary, all invoices are issued net and if not disputed in good faith in writing before the due
date, will be paid in full without any deductions, deferment or set off (except as expressly permitted herein) by Customer within [***] or such other address as Horizon may provide in writing pursuant to Clause 18.11. If Customer disputes an
invoice, Customer shall notify AGC in writing of the dispute before the due date of the invoice, which notice must include a detailed description of the dispute and, if applicable, the relevant contract provisions. The Parties shall use reasonable
efforts to resolve the dispute as quickly as possible. If the dispute is not resolved within [***] days after the date of Customer’s notice, the CEOs or designated persons of at least vice president level of the Parties shall meet and attempt
in good faith to resolve the dispute. If the dispute remains unresolved [***] days after such individuals undertake to resolve such dispute, then Customer shall, on written request of AGC, pay the disputed portion to a mutually acceptable escrow
agent to be held pending resolution of the dispute. 
  

	 	7.7	 Customer shall pay to AGC, in addition to the Batch Price and the charges for the Raw Materials, a sum in
respect of AGC’s storage of Raw Materials purchased by AGC for the Services as set forth in Appendix Two (“Storage Cost”). AGC shall invoice Customer on a [***] basis for the Storage Cost incurred during the Services.

  

	 	7.8	 Raw Materials and shipping costs for all Services will be invoiced to Customer as set forth in Appendix Two.

 Late Payments 
  

	 	7.9	 If the portion of an undisputed invoice is not settled by Customer in full in accordance with this Agreement
and after providing the Customer with [***] days prior written notice to settle such undisputed portion of an invoice following the due date therefor, AGC may, at its discretion: 

 

	 	7.9.1	 charge Customer, which Customer will pay, interest at a rate of [***]% per month on the sums overdue on a
compounded basis until payment is received in full and/or; 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	  
 COMMERCIAL SUPPLY AGREEMENT
	  	

 29 

 CONFIDENTIAL 

 

	 	7.9.2	 until the portion of the invoice is received in full, suspend the performance of the Services, provided that
AGC has provided Customer with [***] days prior written notice of its intent to suspend the Services. Where performance is suspended, AGC shall have no liability to Customer for such suspension or delay in the Timeline and the Batch Price for any
Batches that are the subject of a Binding Order which are delayed or cancelled as a result of the suspension shall become due and payable by Customer. 

Payments due to Customer 
  

	 	7.10	 Where any payment, credit or refund is properly due to the Customer under this Agreement, the Customer can
elect to: 

  

	 	7.10.1	 have that amount refunded to it by AGC on [***] days’ notice; or 

 

	 	7.10.2	 have that amount set-off against any further amount payable by the
Customer under this Agreement or any future agreement the Parties enter into. 

  

	 	7.11	 Where Customer elects to have an amount set-off against any further
amount payable by the Customer under this Agreement and, subsequent to that credit, the Customer remains entitled to a payment, credit or refund, AGC shall refund that amount to the Customer within [***] days of the Customer requesting AGC refund
that amount. 

  

	8.	 CUSTOMER AUDITS, REGULATORY INSPECTIONS & MATTERS 

Audits 
  

	 	8.1	 Customer’s audit rights are as set forth in the Commercial Quality Agreement. 

Regulatory Inspections 
  

	 	8.2	 Regulatory inspections are addressed in the Commercial Quality Agreement. AGC shall upon reasonable notice and
during reasonable times make available facilities, documents, information and/or personnel as are reasonably necessary or useful pursuant to and during regulatory inspections by Regulatory Authorities as further set forth in the Commercial Quality
Agreement. 

 Regulatory Filings and Standards 

 

	 	8.3	 During the preparation for filing with any Regulatory Authority of any documentation which is or is
equivalent to the Regulatory Authority’s Chemistry and Manufacturing Controls (“Authority Submission”) portion of applicable approval application, including any New Drug Application, Abbreviated New Drug Application (ANDA), Marketing
Approval Application (MAA) or other approval, as the case may be, Customer shall provide AGC with a copy of the relevant Authority Submission portion as well as all material supporting documents which have been relied upon to prepare the Authority
Submission portion so as to permit AGC to verify that the Authority Submission portion accurately describes the work that AGC has performed and the manufacturing processes that AGC will perform pursuant to this Agreement. AGC shall provide Customer
with its comments within [***] Business Days from receipt of the documents. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 30 

 CONFIDENTIAL 

 

	 	8.4	 For clarity, the Parties agree that in reviewing the documents referred to in Clause 8.3 above,
AGC’s role will be limited to verifying the accuracy of the description of the work undertaken or to be undertaken by AGC. As such, AGC shall not assume responsibility or liability for the accuracy of the filings with Regulatory Authorities
other than for information provided by AGC in writing and intended for inclusion in regulatory filings. The sole responsibility of the preparation and filing of all regulatory documents with the Regulatory Authorities shall be borne by Customer.

  

	 	8.5	 Customer shall provide to AGC: 

 

	 	8.5.1	 all documents reasonably necessary or reasonably requested by AGC relating to any Regulatory Authority’s pre-approval inspection of AGC’s Facility, including but not limited to, development reports, Chemistry and Manufacturing Controls documentation and stability data, subject to Customer being able to legally
provide such documents to AGC; and 

  

	 	8.5.2	 to the extent reasonably practicable, at least [***] days prior to [***] by AGC, Customer shall [***].

  

	 	8.6	 AGC will provide Customer with information and data regarding the manufacture of Product to the extent
reasonably requested by Customer or necessary for Customer to prepare and defend any inquiries from the FDA or other Regulatory Authorities to satisfy regulatory requirements with respect to Product. Without limiting the foregoing,

  

	 	8.6.1	 AGC shall provide regulatory support to Customer for a Regulatory Authority’s pre-approval inspection, or PAI, of the AGC Facility and during review of any Regulatory Authority submission at a cost specified in Appendix Two. AGC shall allocate the costs of any post-approval inspection equally
among its commercial customers. 

  

	 	8.6.2	 Customer will inform AGC of requests for information from Regulatory Authorities during review of a Regulatory
Authority submission for which AGC support is needed. AGC will use [***] to adhere with the turn-around times requested by Customer to support such regulatory responses. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	  
 COMMERCIAL SUPPLY AGREEMENT
	  	

 31 

 CONFIDENTIAL 

 

 Person in Plant 

 

	 	8.7	 On reasonable advance notice to AGC, Customer’s employees or representatives may be present at the
AGC’s facilities to observe Product and BDS manufacture, subject to AGC’s reasonable site rules, regulations and room capacity constraints. 

  

	9.	 WARRANTIES 

Customer Warranties 
  

	 	9.1	 Customer warrants and represents to AGC that: 

 

	 	9.1.1	 it has the right to supply and deliver to AGC the Customer Materials (including the Cell Line provided by or on
behalf of Customer where applicable) and the Customer Intellectual Property Rights and AGC has the right to use the same for the Services and the manufacture of Product, in each case in accordance with this Agreement; 

 

	 	9.1.2	 to the best of its knowledge as of the Effective Date, the Materials Safety Data Sheets for the
Customer-Provided Materials are accurate and the Customer-Provided Materials are free from all contaminants including, without limitation, virus, bacteria or other vectors. Customer will advise AGC immediately of any safety or toxicity issues of
which it becomes aware regarding the Customer-Provided Materials that are not included in the applicable Materials Safety Data Sheet; 

  

	 	9.1.3	 to the best of its knowledge as of the Effective Date, AGC’s use of any of the Cell Line, Customer
Materials, Customer Intellectual Property Rights and the Process, and AGC’s manufacture of Product, in each case in accordance with this Agreement, will not infringe any Intellectual Property of Third Parties; 

 

	 	9.1.4	 the license of or other access to Customer Intellectual Property Rights to AGC for the Services is lawfully
granted; and 

  

	 	9.1.5	 to the best of its knowledge as of the Effective Date, the Cell Line and Process provided by or on behalf of
the Customer and Customer-Provided Materials are viable, adequate and suitable for the effective performance of the Services and manufacture of Product according to Specification. 

AGC Warranties 
  

	 	9.2	 AGC warrants and represents to Customer that: 

 

	 	9.2.1	 its permits and regulatory licenses applicable for the Services and the manufacture of the Product are valid;

  

	 	9.2.2	 to the best of AGC’s knowledge as of the Effective Date, it has the necessary facilities, Third Party
contractors and skilled personnel that may be reasonably anticipated to be necessary of a biologics contract manufacturer for the regular provision of manufacturing and development services of biologic material and required for performance of the
Services in accordance with this Agreement; 

  

			
		  	
	COMMERCIAL SUPPLY AGREEMENT	  	

 32 

 CONFIDENTIAL 

 

	 	9.2.3	 all Deliverables shall be Delivered free of encumbrances or liens but for the avoidance of doubt no warranty is
given in this Clause 9.2.3 in respect of non-infringement of Third Party Intellectual Property or freedom to use; 

 

	 	9.2.4	 to the best of its knowledge as of the Effective Date, AGC’s use of the AGC Intellectual Property Rights
used in the Services will not infringe any Third Party Intellectual Property, except that no warranty is given to the extent that infringement arises due to the combination of AGC Intellectual Property Rights used together with the Cell Line,
Process, Customer Materials and Customer Intellectual Property Rights and would not occur when the AGC Intellectual Property Rights are used in the production of biologics generally (“Customer-Specific Infringement”);

  

	 	9.2.5	 All Product manufactured and supplied under this Agreement and released with a Certificate of Analysis by AGC
shall at the date of release conform to the specifications set forth in that Certificate of Analysis; 

  

	 	9.2.6	 All Product manufactured under this Agreement shall be manufactured, handled, stored, labelled, packaged and
transported in accordance with applicable cGMP requirements, the Commercial Quality Agreement, the applicable BLA and all applicable laws, rules, regulations and guidances in the US or EU (including, without limitation, Section 262 of the PHS
Act); 

  

	 	9.2.7	 No Product manufactured and supplied under this Agreement shall be (a) adulterated or misbranded within
the meaning of the U.S Food, Drug and Cosmetics Act (“FD&C Act”), or (b) an article that may not be introduced into interstate commerce under the provisions of Sections 404 or 505 of the FD&C Act; and

  

	 	9.2.8	 AGC shall not use in any capacity the services of any persons debarred under 21 U.S.C. sections 335 (a) and 335
(b) in connection with the manufacture of Product under the Agreement. 

 Mutual Warranties 

 

	 	9.3	 Each Party warrants and represents to the other that: 

 

	 	9.3.1	 it has the right and corporate authority to enter into this Agreement and perform its obligations hereunder;

  

	 	9.3.2	 it will comply with all applicable laws, rules and regulations in connection with its performance under this
Agreement; and 

  

			
		  	
	  
 COMMERCIAL SUPPLY AGREEMENT
	  	

 33 

 CONFIDENTIAL 

 

	 	9.3.3	 it shall obtain and during the Term maintain in force all applicable permits and regulatory licenses required
in connection with the handling, transport and storage of the Cell Line and Product and performance of the Services. 

Exclusion of other express and implied warranties 
  

	 	9.4	 Except as provided in this Agreement, to the maximum extent permitted by applicable law, except for those
express warranties set out above, the Parties neither make nor give any other express or implied (whether by statute, custom or otherwise) warranties in relation to each of their respective obligations, duties or activities owed or performed under
this Agreement and hereby exclude any other such express or implied warranty in respect of that subject matter. 

  

	10.	 CONFIDENTIAL INFORMATION 

 

	 	10.1	 In consideration of one Party (the “Disclosing Party”) making available its Confidential
Information to the other (the “Recipient Party”), the Recipient Party hereby undertakes that it shall: 

  

	 	10.1.1	 treat and safeguard as private and confidential all the Disclosing Party’s Confidential Information;

  

	 	10.1.2	 use the Disclosing Party’s Confidential Information only during the Term for those purposes reasonably
necessary for the fulfilment of its obligations or exercise of its rights under this Agreement; 

  

	 	10.1.3	 ensure the proper and secure storage of the Disclosing Party’s Confidential Information applying no less
stringent than standards applied to protection of Recipient Party’s own confidential information but, in any event, no less that reasonable care; and 

  

	 	10.1.4	 not at any time without the Disclosing Party’s prior written consent disclose or reveal, whether directly
or indirectly, any of the Disclosing Party’s Confidential Information to any person whatsoever except its and its Affiliates’ directors, officers, employees, contractors (including Testing Laboratories), advisors and representatives
(“Permitted Recipients”) who have a need to know such information for the purposes hereof and who, prior to the receipt of such Confidential Information, are subject to legally enforceable obligations of confidentiality and non-use at least as stringent as those set forth herein. The Recipient Party shall remain directly responsible to the Disclosing Party for any non-compliance with this
Agreement by any of the Recipient Party’s Permitted Recipients. 

  

	 	10.2	 The Recipient Party’s obligations in this Agreement regarding the Disclosing Party’s Confidential
Information do not apply to information: 

  

			
		  	
	COMMERCIAL SUPPLY AGREEMENT	  	

 34 

 CONFIDENTIAL 

 

	 	10.2.1	 which, at the time of its disclosure by the Disclosing Party or generation hereunder, was generally available
to the public; 

  

	 	10.2.2	 which becomes generally available to the public after such disclosure or generation other than by reason of a
breach of any of the undertakings in this Agreement by the Recipient Party or its Permitted Recipients; 

  

	 	10.2.3	 which is, at the time of such disclosure or generation, and as evidenced by the Recipient Party’s written
records, lawfully already within the Recipient Party’s possession; 

  

	 	10.2.4	 was lawfully disclosed to the Recipient Party on a non-confidential
basis by a Third Party who is not subject to an obligation of confidentiality with respect to such Confidential Information; or 

  

	 	10.2.5	 was discovered or created by or for the Recipient Party without the use, application or benefit of any of the
Disclosing Party’s Confidential Information. 

  

	 	10.3	 The Recipient Party may disclose the Disclosing Party’s Confidential Information hereunder:

  

	 	10.3.1	 to the extent such disclosure is reasonably necessary for prosecuting or defending litigation, complying with
applicable laws or regulations, or exercising its rights or fulfilling its obligations hereunder; provided that if the Recipient Party is required by law or regulation to make any such disclosure of the Disclosing Party’s Confidential
Information it shall, except where impracticable for necessary disclosures (for example in the event of medical emergency), give reasonable advance notice to the Disclosing Party of such disclosure requirement and shall use its reasonable efforts to
assist the Disclosing Party to secure a protective order or confidential treatment of such Confidential Information required to be so disclosed; and 

  

	 	10.3.2	 such disclosure is reasonably necessary: (a) to such Party’s directors, attorneys, independent
accountants or financial advisors for the sole purpose of enabling such directors, attorneys, independent accountants or financial advisors to provide advice to such Party, provided that in each such case on the condition that such directors,
attorneys, independent accountants and financial advisors are bound by confidentiality and non-use obligations substantially consistent with those contained in this Agreement; or (ii) to actual or
potential investors, acquirors, merger partners, (sub)licensees and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition, merger, collaboration or other
transaction; provided that in each such case on the condition that such Persons are bound by confidentiality and non-use obligations substantially consistent with those contained in the Agreement, and
Recipient Party shall remain directly responsible to Disclosing Party for any breach by any such Person of such obligations. 

  

			
		  	
	  
 COMMERCIAL SUPPLY AGREEMENT
	  	

 35 

 CONFIDENTIAL 

 

	 	10.4	 Other than the limited and restricted rights of use set out in this Clause 10 and in Clause 11,
nothing in this Agreement intends to or has the effect of granting any right, title, license or interest in or to the Recipient Party or Permitted Recipients in respect of the Disclosing Party’s Confidential Information. 

 

	 	10.5	 If the Recipient Party or any of its Permitted Recipients becomes aware of any misuse of the Confidential
Information or a breach or threatened breach of this Clause 10 occurs or becomes apparent, the Recipient Party shall inform the Disclosing Party in writing of such obligation or fact as soon as possible after it is informed, or becomes aware,
of it and if possible, before any Confidential Information is disclosed, so that (if the Disclosing Party in its absolute discretion shall see fit) a protective order or other appropriate remedy may be sought. The Recipient Party agrees to
reasonably assist and co-operate (and shall procure that each of its Permitted Recipients shall, as appropriate, assist and co-operate) in any action which the
Disclosing Party may decide to take. 

  

	 	10.6	 Upon termination or expiry of this Agreement or at the request of the Disclosing Party, the Recipient Party
shall at its election promptly destroy or return to the Disclosing Party any and all Confidential Information (including copies of documents, computer records and records on all other media) then in its possession or under its control except where
such Confidential Information is covered under surviving license rights between the Parties. Notwithstanding the foregoing, (a) each Recipient Party may retain a single copy of any document contained the Disclosing Party’s Confidential
Information solely for the purpose of determining the scope of the obligations under this Agreement, and (b) the Recipient Party may retain any electronic copies of the Disclosing Party’s Confidential Information held securely in the
Recipient Party’s electronic backup storage in accordance with its established document retention policies; subject in each case to the Recipient Party’s continuing confidentiality and non-use
obligations under this Agreement with respect to such Confidential Information. 

  

	 	10.7	 The Parties acknowledge that they have received Confidential Information under other agreements between each
other. The Parties hereby agree that Confidential Information received under those earlier agreements may be used for the purposes of performing the Services under this Agreement. 

 

	 	10.8	 The provisions of this Clause 10 shall survive termination of the Agreement for a period of [***] years.

  

	 	10.9	 For the avoidance of doubt, the provisions of this Clause 10 do not restrict the Customer’s right
to disclose or otherwise use and exploit the Deliverables after such Deliverables have been Delivered to the Customer. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 36 

 CONFIDENTIAL 

 

 Party’s Names & Press Release 

 

	 	10.10	 Except as otherwise provided for in this Agreement or required by any applicable law, regulation or order of an
administrative agency or court of competent jurisdiction, neither Party shall use the name of the other Party or of the other Party’s Affiliates, directors, officers or employees in any advertising, news release or other promotional release
without the prior consent of the other Party, which shall not be unreasonably withheld or delayed. 

  

	11.	 INTELLECTUAL PROPERTY  

Pre-Existing Intellectual Property 

 

	 	11.1	 Any Intellectual Property owned or Controlled by a Party as of the Effective Date or developed or acquired by
such Party during the Term independently from this Agreement without use of the other Party’s Confidential Information (“Background Technology”) shall, as between the Parties, remain the sole and absolute property of the Party
that owns or Controls such Background Technology. Nothing in this Agreement shall act as any assignment or transfer of either Party’s Background Technology. A Party’s Background Technology shall not be licensed to the other Party under
this Agreement unless an express license is granted hereunder. 

 Customer’s grant of Intellectual Property
License for the Services  
  

	 	11.2	 The Customer hereby grants to AGC for the Term a non-exclusive,
royalty-free, sublicensable (solely with the prior written consent of the Customer), limited license under the Customer Background Technology and Customer Agreement IPR solely to the extent the same is required and necessary for the proper
performance of the Services. This license: 

  

	 	11.2.1	 does not prevent the Customer from granting a license to or making any use of its Background Technology or
Customer Agreement IPR; and 

  

	 	11.2.2	 terminates automatically upon the expiry or termination of this Agreement, whichever is the earlier.

 Intellectual Property created in the course of the Services 

 

	 	11.3	 Without affecting Clauses 11.1 and 11.2, all data, results, information, processes, materials,
trade secrets, know-how and corresponding Intellectual Property newly generated by AGC in its performance of the Services and to the extent [***] (“Customer Agreement IPR”) shall be solely and
exclusively owned by Customer. AGC hereby assigns to Customer all right, title and interest in and to all Customer Agreement IPR. AGC shall cooperate with Customer and execute any appropriate documents to fully effect the foregoing. All Customer
Agreement IPR shall be deemed to be Customer’s Confidential Information. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 37 

 CONFIDENTIAL 

 

	 	11.4	 All Intellectual Property other than Customer IPR generated by AGC under the Services that is useful for
general biologics manufacturing activities shall be owned by AGC (“AGC IPR”). 

  

	 	11.5	 In the event that [***]. 

License to AGC IPR 
  

	 	11.6	 AGC hereby grants to Customer a general, royalty free, sub-licensable,
worldwide, perpetual license to use AGC Intellectual Property Rights and AGC IPR to the extent that the same is necessary or useful for the exploitation of the Product or use of the Cell Line or Process to manufacture the Product. Except to
Permitted Recipients or as otherwise provided in this Agreement, nothing in the foregoing shall permit Customer to make any disclosure of AGC’s Confidential Information (including AGC’s Know-How) to
a Third Party without the express prior written consent of AGC, not to be unreasonably withheld, conditioned or delayed. This license does not prevent AGC granting a license to or making any use of AGC Intellectual Property Rights or AGC Agreement
IPR. 

 Right to file for protection 
  

	 	11.7	 Each Party may file patent protection on any Intellectual Property it owns in accordance with this Clause
11 above and the other Party shall promptly upon request co-operate at the requesting Party’s reasonable expense, with any requests to assist or enable the Party’s protection including but not
limited to signing and delivering documents and other information necessary for the valid application and prosecution of any such patent. 

Notice of Infringement 
  

	 	11.8	 Each Party will promptly notify the other Party of any allegation of infringement or misappropriation of any
Third Party Intellectual Property due to the handling, storage or use of the Cell Line, Customer Materials, Customer Intellectual Property Rights, AGC Intellectual Property Rights or manufacture of Product hereunder. 

Use of Company Materials, Products and Deliverables. 
  

	 	11.9	 AGC will use the Customer Materials, Products, Deliverables and any documents relating thereto only for the
conduct of the Services, and not for any other purpose without Customer’s prior written consent. AGC will retain control over the Customer Materials, Products, Deliverables and any documents relating thereto and, except as expressly agreed in
writing by 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 38 

 CONFIDENTIAL 

 

 Customer, will not transfer or otherwise provide access to any Customer Materials, Products,
Deliverables or any documents relating thereto to any other Persons other than those performing Services hereunder and who are subject to like written obligations to protect the Customer Materials, Products, Deliverables and any documents relating
thereto. The Customer Materials, Products and Deliverables may have unknown characteristics and AGC will therefore use prudence and reasonable care in the use, handling, storage, transportation and disposition and containment of the Customer
Materials, Products and Deliverables. 
  

	12.	 INDEMNITIES AND LIABILITY  

Indemnity of AGC 
  

	 	12.1	 (a) Subject to Section 12.3, and to the extent permitted by applicable law, Customer shall promptly
indemnify, defend and hold harmless AGC and each of its directors, officers, employees, contractors (including Testing Laboratories) and representatives (the “AGC Parties”) against any and all losses, demands, claims, liabilities,
damages, costs and expenses (including but not limited to, court costs and reasonable documented attorney’s fees and expenses together with any applicable taxes thereon) (“Liabilities”) arising from any claim, action or
proceeding brought or initiated by a Third Party (a “Claim”) that the AGC Parties may or have suffered or incurred directly as a result of the following: (i) any actual or alleged infringement or misappropriation of any Third
Party Intellectual Property due to AGC’s use of the Cell Line, Process, Customer Intellectual Property Rights, Customer-Provided Materials, or performance of the Services or manufacture of Product in accordance with this Agreement;
(ii) the use, handling, distribution, marketing, sale of the Product manufactured hereunder by or on behalf of a Customer Party; (iii) injury or death caused by the administration of Product manufactured hereunder; (iv) negligence,
gross negligence or intentional misconduct committed by a Customer Party; or (v) breach of this Agreement (including any representation or warranty) by Customer. 

(b) [***] 
 (c) The
foregoing indemnities shall not apply to the extent the Claims or Liabilities arose from the negligence, gross negligence, breach of this Agreement or the Commercial Quality Agreement, or intentional misconduct of any AGC Party, are attributable to
the AGC Materials or are covered by an indemnity under Clause 12.2. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 39 

 CONFIDENTIAL 

 

 Indemnity of Customer 

 

	 	12.2	 Subject to Section 12.3, and to the extent permitted by applicable law, AGC shall promptly indemnify and
hold harmless Customer and each of its directors and officers, employees, agents, contractors or representatives (“Customer Parties”) against any and all Liabilities arising from a Claim that the Customer Parties may or have
suffered or incurred directly as a result of the following: (i) inaccurate Certificates of Analysis such that the certified Product at the time of Delivery does not meet Specification when certified to meet Specification, failure to manufacture
Product according to cGMP, use of improper Batch records, use of contaminated and/or inappropriate Raw Materials; (ii) negligence, gross negligence or intentional misconduct committed by a AGC Party; (iii) breach of this Agreement
(including any representation or warranty) by AGC; (iv) any failure of the AGC Materials; or (v) any actual or alleged infringement or misappropriation of any Third Party Intellectual Property due to AGC’s use of the AGC Intellectual
Property Rights that is not a Customer-Specific Infringement. 

 The foregoing indemnities shall not apply to the extent
the Claims or Liabilities arose directly from the negligence, gross negligence, breach of this Agreement or the Commercial Quality Agreement or intentional misconduct by any Customer Party or are covered by an indemnity under Clause 12.1.

 Indemnification Procedure 
  

	 	12.3	 The Party (the “Indemnitee”) that intends to claim indemnification under this Clause 12
shall: 

  

	 	12.3.1	 promptly, and in any event within [***] Calendar Days of it receiving notice of the Claim, threat or action,
notify the other Party (the “Indemnitor”) in writing in general terms of any Claim, threat or action which has or has the potential to give rise to the Indemnitee seeking to rely on and claim the benefit of the indemnification
together with notification of the Indemnitee’s intention to rely on such indemnity, provided that, failure to give such notice shall not relieve the Indemnitor of its indemnification obligations except and only to the extent such failure
actually and materially prejudices the ability of the Indemnitor to defend against such Claims, provided that that the foregoing shall not prevent the Indemnitee from complying with the procedural requirement of any proceedings which have been
commenced; 

  

	 	12.3.2	 not prejudice any defense to any Claim or attempt to settle or compromise such claim; 

 

	 	12.3.3	 subject to its other rights and obligations and compliance with the procedures set out in this Clause
12, permit the Indemnitor to have overall control of the conduct of the negotiations and the proceedings including any counterclaim; 

  

	 	12.3.4	 cooperate as reasonably requested by the Indemnitor, at the Indemnitor’s expense, in the conduct of such
Claim (and any counterclaim); and 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 40 

 CONFIDENTIAL 

 

	 	12.3.5	 have the right (at its own expense) to engage independent counsel and participate in all proceedings and
negotiations whether named or not as a party in the Claim or proceedings. 

  

	 	12.4	 Notwithstanding any other provision in this Clause 12, the Indemnitor shall not settle or consent to an
adverse judgement in any such claim, demand, action or other proceeding that adversely affects the rights or interests of any Indemnitee or imposes additional obligations (financial or otherwise) on such Indemnitee, without the prior express written
consent of such Indemnitee (such consent to be at the Indemnitee’s sole discretion). 

 Insurance 

 

	 	12.5	 Customer shall procure from a reputable insurance carrier commercial general liability insurance including
coverage for products and completed operations and contractual liability (including coverage for advertising and personal injury) with a combined single limit of no less than [***] dollars ($[***]) per occurrence and [***] dollars ($[***]) in
the aggregate. Customer will maintain such insurance during the Term of this Agreement and for [***] years after the last sale of a Commercial Product, subject to continued availability at commercially reasonable rates. Upon reasonable request,
Customer will deliver a certificate of insurance evidencing such coverage and an endorsement of additional insured in favor of AGC. 

  

	 	12.6	 AGC shall maintain, at its expense, comprehensive general liability insurance and workers compensation
insurance, including product liability insurance, in the amount of [***] dollars ($[***]) per occurrence and [***] dollars ($[***]) in the aggregate. All insurance required under this Agreement shall be maintained during the Term, and AGC shall from
time to time provide copies of certificates of such insurance to Customer upon reasonable request. Notwithstanding the preceding sentence, AGC shall be obligated to maintain product liability insurance obtained by it pursuant to this Clause
12.6 during the Term and after expiration or termination of this Agreement for a period [***] years following the Commercial Product expiration date for the last lot of Commercial Product delivered hereunder. 

 

	 	12.7	 Each Party will provide the other Party with at least [***] days’ written notice prior to non-renewal, termination or modification of their respective insurance coverage as described above. 

Limitation of Liability 
  

	 	12.8	 The Parties represent and acknowledge that they have negotiated the terms of this Agreement and have reached
agreement on the terms based on their own assessment of their own risks, liabilities and rewards in connection with this Agreement and the Product in addition to having had the benefit of professional legal advice and accordingly the Parties agree
that, without prejudice to Clauses 12.9 and 12.10, AGC’s aggregate liability to Customer for any loss or damage suffered by Customer, as a result of breach of this Agreement or of any other liability (including but not limited to negligence,
misrepresentation or claim under the indemnities) in respect to any claim arising under this Agreement or in connection with the Services shall be limited to the lesser of (a) the total amounts paid by Customer hereunder [***], or (b) [***]
euros (€[***]). 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 41 

 CONFIDENTIAL 

 

	 	12.9	 Neither AGC nor Customer shall be liable for any loss or damage howsoever caused (even if foreseeable or
in the contemplation of AGC or Customer) in respect of: 

  

	 	12.9.1	 loss of indirect profits, business, business opportunities or revenue; and 

 

	 	12.9.2	 special, indirect or consequential loss. 

 

	 	12.10	 Notwithstanding the foregoing, nothing in this Agreement shall purport or attempt or serve to exclude or
restrict any liability for (i) gross negligence or intentional misconduct; (ii) any fraud or fraudulent misrepresentation; (iii) amounts owing by a Party under Clause 7 (subject to Clause 14.4); (iv) claims subject to
Customer’s indemnification obligations under Clause 12.1(a); or (v) a breach of confidentiality. 

  

	13.	 PRODUCT RECALL 

 

	 	13.1	 Subject to Clause 13.3.1, the costs and obligations with respect to any Recall of Product and handling
enquiries and contacts from any Regulatory Authority relating to any Recall of Product shall be the responsibility of Customer. Customer shall notify all Regulatory Authorities having jurisdiction over Product (whether or not the issue arose in the
jurisdiction controlled by the Regulatory Authority) of any Recall, and shall be responsible for coordinating all necessary activities regarding the action taken. AGC shall, at Customer’s expense, provide all reasonable assistance to Customer
in connection with any Recall. The Parties agree to keep each other advised of any Recall, the progress of undertaking any Recall, and to exchange copies of such documentation as may be reasonably required, to assure regulatory compliance with a
Recall. 

  

	 	13.2	 If either Party has reason to believe that any Product (whether the Product itself or particular Batch(es))
should be Recalled, such Party shall promptly inform the other in writing, to also include the reasons and explanations for the Recall, prior to taking any such action. In addition, Customer shall give AGC prompt written notice of any Recalls that
Customer believes were caused by or may have been caused by AGC’s failure to comply with its obligations under this Agreement. 

  

	 	13.3	 If any Product is Recalled for safety reasons or due to a mandatory notification from a Regulatory Authority
dictating the Recall and, in either case, such reasons are directly a result of AGC’s failure to manufacture Product in accordance with the terms of this Agreement or the Commercial Quality Agreement or [***] (“Manufacturing
Failure”), then AGC shall, subject to Clause 12, reimburse Customer for all reasonable expenses actually and properly incurred by Customer in undertaking the Recall of those

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 42 

 CONFIDENTIAL 

 

	 	
specific Products which are the subject of a Manufacturing Failure. Such payment shall be made within [***] days of Customer providing AGC will a detailed breakdown of such costs and
responses to all requests for clarification by AGC with respect thereto. If AGC disputes that the Recall is: 

  

	 	13.3.1	 due to safety reasons or mandatory notification from a Regulatory Authority dictating the Recall then the
Parties shall mutually select a regulatory expert to evaluate whether the Recall was appropriate to address the safety reason or comply with the Regulatory Authority’s notice (as applicable); and/or 

 

	 	13.3.2	 due to AGC’s Manufacturing Failure, then the Parties shall mutually select an independent laboratory to
evaluate whether the Product is Defective due to AGC’s Manufacturing Failure; and 

 the evaluation(s) by the
regulatory expert and/or independent laboratory shall be binding on the Parties (other than where such decision is a manifest error). If such evaluation upholds any part of AGC’s dispute then the Parties shall share the costs of the Recall pro
rata. Subject to Clauses 9 and 12, any payment by AGC under this Clause 13.3 shall be Customer’s sole remedy for the costs of the Recall. 
  

	14.	 TERM AND TERMINATION 

 

	 	14.1	 This Agreement shall commence on and have effect as of the Effective Date and will, subject to earlier
termination in accordance with this Clause 14 or otherwise, continue until terminated by either Party upon at least three years notice (and provided that such notice cannot be provided prior to the 4th anniversary of the Effective Date)(the “Term”). 

  

	 	14.2	 Customer may terminate this Agreement (a) in accordance with Clause 5.13, or (b) immediately
upon written notice if does not obtain regulatory approval for the Product in a major market. 

 Events of
Termination 
  

	 	14.3	 Either Party (“Non-Defaulting Party”) may terminate
this Agreement before expiry of the Term with immediate effect upon prior written notice to the other Party (“Defaulting Party”) if: 

  

	 	14.3.1	 the Defaulting Party fails to pay any undisputed sum payable under this Agreement within sixty
(60) Calendar Days of notice demanding payment served after expiry of the original payment term stipulated in Clause 7; 

  

	 	14.3.2	 the Defaulting Party commits a material breach of its obligations under this Agreement and if the breach is
capable of remedy, fails to remedy it during a period of thirty (30) Calendar Days starting on the date of receipt of notice from the Non-Defaulting Party generally identifying the breach and requiring it
to be remedied; 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 43 

 CONFIDENTIAL 

 

	 	14.3.3	 the Defaulting Party is (i) generally unable to pay its debts as they become due; or (ii) has an
administrator appointed or administration order made against it or an order for winding-up or dissolution made (otherwise than in the course of a bona fide reorganization previously approved in writing by the Non-Defaulting Party) or liquidator appointed and such step is not withdrawn within thirty (30) Calendar Days; 

  

	 	14.3.4	 any material permit or regulatory license is permanently revoked preventing the performance of the Services by
the Defaulting Party. 

 Effect of Termination 

 

	 	14.4	 Upon termination of this Agreement, Customer shall pay to AGC: 

 

	 	14.4.1	 payments due by Customer to AGC in respect of Services performed in accordance with the terms and conditions of
this Agreement and the Commercial Quality Agreement, up to and including the day of such termination in full for all completed stages and for partially completed stages a sum calculated on a pro-rata basis
having regard to the Batch Price for the cancelled stages (fairly determined by the Project Team having regard to man hours, materials, profit element and irreversible commitments incurred by AGC), less any amounts due to Customer by AGC;

  

	 	14.4.2	 if Customer is the Defaulting Party under Clause 14.3 or upon termination under Clause 5.13 if the
Supply Failure results from Customer’s negligence, willful misconduct or breach of this Agreement: 

  

	 	14.4.2.1	 in respect of Binding Orders in existence at the date of termination, a payment calculated as [***],
provided that if the effective date of termination is on or after [***], such amounts shall be [***]; 

  

	 	14.4.2.2	 If the Customer failed to order the Minimum Volume in the Calendar Year of such termination, then Customer
shall pay to AGC a sum calculated as [***], provided that if the effective date of termination is on or after [***], such amounts shall be [***]; and 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 44 

 CONFIDENTIAL 

 

	 	14.4.4.2.3	 [***] 

  

	 	14.4.3	 If this Agreement is terminated pursuant to Clause 14.2(b), then AGC’s sole remedy shall be [***].

  

	 	14.4.4	 If the amounts owed by AGC to Customer as of the effective date of termination are greater than the amounts
owed to AGC by Customer as of such date, then AGC shall refund the difference to Customer. 

  

	 	14.4.5	 payments due at the time of termination pursuant to Clauses 7.10, 7.11 and/or 14 are to be made
within [***] days of the effective date of termination. 

  

	 	14.5	 Upon termination of this Agreement for any reason, provided the Customer has paid all undisputed sums
outstanding and which are properly due under this Agreement, AGC shall, within [***] Calendar Days of: 

  

	 	14.5.1	 those payments having been made; or 

 

	 	14.5.2	 the date of termination of this Agreement, 

(whichever is the later) provide the Customer with all Deliverables then manufactured or generated and all transferable work in progress and
all Product then manufactured in accordance with Clause 6. [***]. 
 Survival 

 

	 	14.6	 Termination or expiry of this Agreement for whatever reason shall not affect the accrued rights or liabilities
of either AGC or Customer arising under or out of this Agreement and all provisions which by their terms would to survive this Agreement and including the provisions of Clauses 2.3 (last two sentences only), 2.4, 2.5 (last sentence only), 3.1,
3.2 (first sentence only), 4.6 (last sentence only), 5.12.4, 6, 7 (excluding 7.2 and 7.3), 8.1, 8.2, 8.5.2, 8.6, 9.2.3, 9.2.5, 9.2.6, 9.2.7, 9.4, 10, 11 (excluding 11.2 and 11.8), 12, 14.4., 14.,5, 14.6, 15, 16, 17 and 18 shall survive
termination or expiry and remain in full force and effect. 

  

	15.	 TECHNOLOGY TRANSFER 

 

	 	15.1	 (i) Upon termination or during the notice period regarding termination of this Agreement or the Services other
than where termination is for material breach by Customer, (ii) on expiry of this Agreement, or (iii) as provided in Clause 5.13.2 or Clause 5.14, Customer may by written notice to AGC seek assistance from AGC with respect to the
transfer to another manufacturer 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 45 

 CONFIDENTIAL 

 

	 	
of the then-current Process solely for the purpose of manufacturing Product (“Technology Transfer”). Following AGC’s receipt of such notice, the Parties will establish, in
good faith, a schedule and plan for effecting such transfer and AGC will thereafter co-operate with Customer in implementing such plan as agreed by the Parties. As part of the Technology Transfer AGC will make
available for collection, subject to any Regulatory Obligations, all Customer Materials, Cell Line and one copy of all documentation (to the extent not previously delivered to Customer) generated pursuant to or used in the Services up to the date of
termination or expiry. The scope of such Technology Transfer will be agreed upon by the Parties and will include at least the following activities: (a) AGC will provide all pertinent information necessary or useful to manufacture the Product or
to support regulatory filings for the Product(s), including, without limitation, analytical testing methods, protocols and reports, Batch production records, master Batch records, production process documentation and standard operating procedures;
(b) AGC will provide reasonable assistance and cooperation in order to enable Customer or its designee to manufacture the Product(s); (c) AGC will provide Company with access to Customer’s employees and contractors with expertise in
manufacturing to answer Customer’s questions related to such transfer; and (d) AGC will use reasonable efforts to assist Customer to secure supply terms for applicable raw materials from Customer’s suppliers of such raw materials and
to identify a Third Party contract manufacturer acceptable to both Parties. 

  

	 	15.2	 The obligations on AGC in respect of the Technology Transfer shall only be exercisable by Customer within a
period ending [***] months after the date of termination or expiry (whichever is the earlier) and AGC shall not be obliged to commit any greater human resources in the Technology Transfer than [***] FTE hours. Except where such Technology Transfer
occurs in connection with AGC’s material breach of this Agreement, Customer shall pay AGC’s costs providing the Technology Transfer at an hourly FTE rate of [***] dollars ($[***]) (to increase annually on the anniversary of the Effective
Date in accordance with the agreed rate of inflation) and all other costs shall be charged at cost value [***]. In no event shall a Technology Transfer under this Agreement exceed $[***], unless otherwise agreed upon by the Parties.

  

	 	15.3	 [***] 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 46 

 CONFIDENTIAL 

 

 [***]. 
  

	16.	 FORCE MAJEURE 

 

	 	16.1	 Neither Party shall be held liable or responsible to the other Party nor be deemed to have defaulted under or
breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement or the Services to the extent, and for so long as, such failure or delay is caused by or results from causes beyond the reasonable control of the
other Party (“Impeded Party”) including but not limited to fires, earthquakes, floods, embargoes, wars, acts of war (whether war is declared or not), terrorist acts, insurrections, riots, civil commotion, strikes, lockouts or other
labor disturbances, other substantial similar acts of nature, omissions or delays in acting by any administrative authority or government agency (except for a failure to comply with applicable laws and regulations) or the other Party (a
“Force Majeure Situation”). 

  

	 	16.2	 The Impeded Party shall notify the other Party in writing of any Force Majeure Situation which prevents the
Impeded Party from complying with an obligation under this Agreement. If a Force Majeure Situation continues for more than [***] months after notice of such Force Majeure Situation is served, and is adversely affecting the performance of this
Agreement, the Party which is not the Impeded Party will have the right, on [***] days’ advance written notice not to expire before the [***] month period to terminate this Agreement. In the case of such termination, Customer will not have a
right to reimbursement for any sums paid under this Agreement for which Services have been rendered or any claim for damages as a result of the termination of this Agreement or non-performance of these
Services. Notwithstanding any other provision under this Clause 16.2, in the event this Agreement is terminated under this Clause 16.2, Customer shall have the right to seek reimbursement or recoupment for any and all amounts for which
Customer has paid Services that were not rendered, including the Reserve Payment. This Clause 16.2 shall not apply to excuse either Party’s payment obligations under this Agreement nor relieve Customer from the payment of Binding Orders.

  

	17.	 APPLICABLE LAW, JURISDICTION AND DISPUTE RESOLUTION 

Applicable Law 
  

	 	17.1	 This Agreement shall be interpreted and governed, and all rights and obligations of the Parties shall be
determined, in accordance with the laws of the state of New York (regardless of choice of law provisions). The Parties waive application of the provisions of the 1980 U.N. Convention on Contracts for the International Sale of Goods, as amended.

  

	 	17.2	 Before resorting to litigation, unless exigent relief is required by either Party as determined in its sole, in
which case such Party shall be free to seek and be granted temporary, injunctive or equitable relief from any court of competent jurisdiction, the Parties shall use their reasonable efforts to negotiate in good faith and settle amicably any dispute
that may arise out of or relate 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 47 

 CONFIDENTIAL 

 

	 	
to this Agreement (or its construction, validity or termination) (a “Dispute”). If a Dispute cannot be settled through negotiations by appropriate representatives of each of the
Parties, either Party may give to the other a notice in writing (a “Dispute Notice”). Within [***] days of the Dispute Notice being given the Parties shall each refer the Dispute to their respective Chief Executive Officers
who shall meet in order to attempt to resolve the dispute. If within [***] days of the Dispute Notice (i) the Dispute is not settled by agreement in writing between the Parties or (ii) the Parties have failed to discuss the Dispute or use
good faith negotiations, the Dispute may be submitted to and finally be settled by the state and federal courts located in the State of New York. The Parties irrevocably: (a) consent and submit solely to jurisdiction and venue of such courts;
(b) agree that such courts will be the sole courts utilized for any Dispute and (c) waive any jurisdictional or venue objections to such courts, including, without limitation, forum non conveniens. Nothing in this MSA shall prohibit (nor
force) the Parties to submit to any other dispute resolution forums as they may between themselves subsequently agree to or discuss. 

  

	18.	 MISCELLANEOUS 

Fundamental Change 
  

	 	18.1	 The occurrence of a Fundamental Change shall not relieve AGC of its responsibility for performance of its
obligations under this Agreement. AGC must promptly: 

  

	 	18.1.1	 notify Customer as soon as AGC is aware that a Fundamental Change has occurred or is reasonably likely to
occur; 

  

	 	18.1.2	 upon request, provide to Customer such further information and written assurances, from AGC and its successors
that there will be no adverse consequences to the supply of Product to Customer or the performance of AGC obligations under this Agreement resulting from the occurrence of the Fundamental Change. Without prejudice to the generality of this Clause
18.1.2, at Customer’s request, AGC and its successors shall provide Customer with written assurances that AGC’s (or its successor’s, as applicable) ongoing corporate and management culture, capacity, capability and financial
viability will continue in a manner sufficient to satisfactorily perform AGC’s obligations under this Agreement. 

  

	 	18.2	 Neither AGC not its successor shall be entitled to terminate this Agreement as a result of a Fundamental
Change. 

  

	 	18.3	 For the avoidance of doubt, a breach of Clause 18.1, shall be deemed to be a material breach of this
Agreement. 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 48 

 CONFIDENTIAL 

 

 Amendment 
  

	 	18.4	 Other than as provided for elsewhere in this Agreement in respect of the Timeline, any modification, extension
or variation of this Agreement (or any document entered into pursuant to or in connection with this Agreement) shall only be valid if it is in writing and signed by or on behalf of each Party to this Agreement. No modification or variation of this
Agreement shall be valid if made by e-mail. 

  

	 	18.5	 Unless expressly so agreed, no modification or variation of this Agreement shall constitute or be construed as
a general waiver of any provisions of this Agreement, nor shall it affect any rights, obligations or liabilities under this Agreement which have already accrued up to the date of such modification or waiver, and the rights and obligations of the
Parties under this Agreement shall remain in full force and effect, except and only to the extent that they are so modified or varied. 

Assignment 
  

	 	18.6	 Except as provided in Clause 18.7, a Party shall not without the prior written consent of the other
Party (such consent not to be unreasonably withheld) assign at law or in equity (including by way of a charge or declaration of trust) or delegate any or all of its obligations under this Agreement, or purport to do any of the same. Any purported
assignment in breach of this clause shall confer no rights on the purported assignee. 

  

	 	18.7	 Customer shall be entitled to assign its rights under this Agreement to any member of Customer’s Group or
to a successor by virtue of a merger, acquisition, Change of Control or sale or transfer of substantially all of its assets to which this Agreement relates. Any assignment made pursuant to this Clause 18.7 shall be subject to the
following terms: 

  

	 	18.7.1	 no assignment shall relieve Customer of any of its obligations under this Agreement that have accrued prior to
the effective date of such assignment; and 

  

	 	18.7.2	 Customer shall provide AGC with prompt written notice of such assignment. AGC may continue to deal exclusively
with Customer in respect of all matters relating to this Agreement at all times until AGC receives such written notice. 

Entire Agreement 
  

	 	18.8	 This Agreement, together with its Appendices, constitutes the entire agreement and understanding of the Parties
with respect to its subject matter and supersedes any previous agreements or understanding between the Parties relating to such subject matter. If any term of this Agreement conflicts with any term of the Commercial Quality Agreement, the
conflicting term of this Agreement shall prevail, except with respect to matters of quality, in which case the conflicting term of the Commercial Quality Agreement shall prevail. For clarity, the Development and Manufacturing Services Agreement
between the Parties dated June 10, 2015 shall continue in full force and effect in accordance with its terms. 

  

			
		  	
	COMMERCIAL SUPPLY AGREEMENT	  	

 49 

 CONFIDENTIAL 

 

 Waiver 
  

	 	18.9	 In no event will any delay, failure or omission (in whole or in part) in enforcing, exercising or pursuing any
right, power, privilege, claim or remedy conferred by or arising under this Agreement or by law, be deemed to be or construed as a waiver of that or any other right, power, privilege, claim or remedy in respect of the circumstances in question, or
operate so as to bar the enforcement of that, or any other right, power, privilege, claim or remedy, in any other instance at any time or times subsequently. 

Severability 
  

	 	18.10	 If any provision of this Agreement shall be found by any court or administrative body of competent jurisdiction
to be invalid or unenforceable, such invalidity or unenforceability shall not affect the other provisions of this Agreement which shall remain in full force and effect. The Parties agree, in the circumstances referred to in this clause to attempt to
substitute for any invalid or unenforceable provision a valid or enforceable provision which achieves to the greatest extent possible the same effect as would have been achieved by the invalid or unenforceable provision. The obligations of the
Parties under any invalid or unenforceable provision of this Agreement shall be suspended while an attempt at such substitution is made. 

Notices 
  

	 	18.11	 Any notice or other communication given or made under this Agreement shall be in writing and in English and
signed by or on behalf of the Party giving it and shall be served by hand, delivering it or sending it by prepaid recorded or special delivery post or prepaid international recorded airmail, to the address and for the attention of the relevant Party
set out in this Clause 18.11 (or as otherwise notified by that Party hereunder). Any such notice shall be deemed to have been received: 

  

	 	18.11.1	 if hand delivered or sent by prepaid recorded or special delivery post or prepaid international recorded
airmail, at the time of delivery; 

  

	 	18.11.2	 if sent by post (other than by prepaid recorded or special delivery post), [***] Business Days from the date of
posting; or 

  

	 	18.11.3	 if sent by airmail (other than by prepaid international recorded airmail), [***] Business Days from the date of
posting; 

 Provided that if deemed receipt occurs before 9.00 a.m. on a Business Day the notice shall be deemed to have
been received at 9.00 a.m. on that day, and if deemed receipt occurs after 5.00p.m. on a Business Day, or on any day which is not a Business Day, the notice shall be deemed to have been received at 9.00a.m. on the next Business Day. 

The addresses of the Parties for the purposes of this Clause 18.11 are: 

[***] 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	COMMERCIAL SUPPLY AGREEMENT	  	

 50 

 CONFIDENTIAL 

 

 [***] 

or such other address as may be notified in writing from time to time by the relevant Party to the other Party. Any such change to the place
of service shall take effect [***] Business Days after notice of the change is received or (if later) on the date (if any) specified in the notice as the date on which the change is to take place. 

Counterparts 
  

	 	18.12	 This Agreement and any amendment hereto may be executed in any number of counterparts and by the Parties to it
on separate counterparts, including by facsimile, .pdf or electronic signature, each of which shall be an original, but all of which together shall constitute one and the same instrument. This Agreement is not effective until each Party has executed
at least one counterpart. 

 No Partnership or Agency 

 

	 	18.13	 Nothing in this Agreement is intended to or shall operate to create a partnership or joint venture of any kind
between the Parties or to authorize either Party to act as agent for the other, and no Party shall have authority to act in the name or on behalf of or otherwise to bind the other in any way (including but not limited to the making of any
representation or warranty, the assumption of any obligation or liability and the exercise of any right or power). Each Party is entering into this Agreement as principal not agent, and may not enforce any of its rights under or in connection with
this Agreement for the benefit of any other person. 

 [Signatures on next page] 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	  
 COMMERCIAL SUPPLY AGREEMENT
	  	

 51 

 CONFIDENTIAL 

 

 THIS AGREEMENT has been executed by or on behalf of the Parties on the date at the top of this
Agreement. 
  

					
	 Signed on behalf of
 CMC
BIOLOGICS A/S, dba AGC Biologics
	 	 )
 )

	by	 		 	 )
 )

	Name :	 	 /s/ Møller
	 	)
	Kasper Møller, PhD	 	)
	Position :	 	General Manager	 	 )
 )

)

		
	 Signed on behalf of
 HORIZON
PHARMA IRELAND LIMITED
	 	 )
 )

	by	 		 	 )
 )

	Name :	 	 /s/ Paul Condon
	 	)
		 	    DIRECTOR	 	)
	Position :	 	Paul Condon	 	)

  

			
		  	
	COMMERCIAL SUPPLY AGREEMENT	  	

 52 

 CONFIDENTIAL 

 

 APPENDIX ONE 

Product Specification and Quality Agreement 

[***] 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	  
 Commercial Supply Agreement –
	  	

 53 

 CONFIDENTIAL 

 

 APPENDIX TWO 

[***] 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	  
 Commercial Supply Agreement –
	  	

 54 

 CONFIDENTIAL 

 

 [***] 

  

			
		  	
	Commercial Supply Agreement –	  	

 55 

 CONFIDENTIAL 

 

 [***] 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	  
 Commercial Supply Agreement –
	  	

 56 

 CONFIDENTIAL 

 

 EXHIBIT A 

AGC’s Standard Form Certificate of Analysis 

[***] 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	  
 Commercial Supply Agreement –
	  	

 57 

 CONFIDENTIAL 

 

 EXHIBIT B 

Standard Form Certificate of Compliance 

[***] 

  

			
		  	[***] = CERTAIN CONFIDENTIAL INFORMATION OMITTED
	  
 Commercial Supply Agreement –
	  	

 58

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]